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A B S T R A C T
Background
Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Clot prevention with anticoagulants might improve
outcomes if bleeding risks are low. This is an update of a Cochrane review first published in 1995, with recent updates in 2004 and
2008.
Objectives
To assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) in people with acute presumed or
confirmed ischaemic stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (June 2014), the Cochrane Central Register of Controlled Trials (CENTRAL),
the Cochrane Database of Systematic Reviews (CDSR), the Database of Reviews of Effects (DARE) and the Health Technology
Assessment Database (HTA) (The Cochrane Library 2014 Issue 6), MEDLINE (2008 to June 2014) and EMBASE (2008 to June
2014). In addition, we searched ongoing trials registries and reference lists of relevant papers. For previous versions of this review, we
searched the register of the Antithrombotic Trialists’ (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug
companies.
Selection criteria
Randomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in people with acute
presumed or confirmed ischaemic stroke.
Data collection and analysis
Two review authors independently selected trials for inclusion, assessed trial quality, and extracted the data.
Main results
We included 24 trials involving 23,748 participants. The quality of the trials varied considerably. The anticoagulants tested were
standard unfractionated heparin, low-molecular-weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Over 90%
of the evidence relates to the effects of anticoagulant therapy initiated within the first 48 hours of onset. Based on 11 trials (22,776
participants) there was no evidence that anticoagulant therapy started within the first 14 days of stroke onset reduced the odds of death
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from all causes (odds ratio (OR) 1.05; 95% confidence interval (CI) 0.98 to 1.12) at the end of follow-up. Similarly, based on eight
trials (22,125 participants), there was no evidence that early anticoagulation reduced the odds of being dead or dependent at the end
of follow-up (OR 0.99; 95% CI 0.93 to 1.04). Although early anticoagulant therapy was associated with fewer recurrent ischaemic
strokes (OR 0.76; 95% CI 0.65 to 0.88), it was also associated with an increase in symptomatic intracranial haemorrhages (OR 2.55;
95% CI 1.95 to 3.33). Similarly, early anticoagulation reduced the frequency of symptomatic pulmonary emboli (OR 0.60; 95% CI
0.44 to 0.81), but this benefit was offset by an increase in extracranial haemorrhages (OR 2.99; 95% CI 2.24 to 3.99).
Authors’ conclusions
Since the last version of the review, no new relevant studies have been published and so there is no additional information to change the
conclusions. Early anticoagulant therapy is not associated with net short- or long-term benefit in people with acute ischaemic stroke.
Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis and pulmonary embolism, but increased bleeding risk.
The data do not support the routine use of any of the currently available anticoagulants in acute ischaemic stroke.
P L A I N L A N G U A G E S U M M A R Y
Anticoagulants for acute ischaemic stroke
Millions of people around the world have strokes every year.Most strokes take place when a blood clot blocks a blood vessel leading to the
brain. Without a proper blood supply, the brain quickly suffers damage, which can be permanent. The damage from a stroke can cause
arm or leg weakness, or difficulties with language or vision. Strokes are sometimes fatal, but will more often leave the survivor unable to
do the things that they used to do. Because strokes are common and cause such damage, researchers are trying to find ways to get rid of
the blood clot soon after the stroke happens. One way to do this is with blood thinning drugs called anticoagulants. If anticoagulants
work, the bad effects of the stroke might be avoided. The main problem with anticoagulants is that they can cause bleeding, which can
sometimes be very serious. This systematic review was designed to find out whether people treated with anticoagulants soon after having
a stroke got better or not, and whether they had problems with bleeding. There is a lot of information in this systematic review - 23,748
people with stroke have been involved in 24 included randomised trials to answer this question. People treated with anticoagulants did
not have less long-term disability, and experienced more bleeding. Anticoagulant treated patients had less chance of developing blood
clots in their legs and in their lungs following their stroke, but these benefits were offset by the increased number of bleeds. This review
did not provide any evidence that the early use of anticoagulants is of overall benefit to people with strokes caused by blood clots. More
research is needed to find out if there are ways to select the people with stroke who will benefit from anticoagulants without suffering
the bleeding complications.
B A C K G R O U N D
Description of the condition
Ischaemic stroke is usually caused by a blood clot blocking flow in
an artery supplying parts of the brain and, in Western countries, is
approximately 10 times more frequent than haemorrhagic stroke
(Andersen 2009). Stroke is the second most common cause of
death in the world (Lozano 2012) and the third most common
cause of disability (Murray 2012). Globally, death and disability
that result from stroke have been increasing in absolute numbers,
with the greatest burden being in low andmiddle income countries
(Feigin 2014).
Description of the intervention
Anticoagulants are agents acting on the coagulation cascade to re-
duce fibrin polymerisation and thrombus formation and are dis-
tinct from thrombolytic and defibrinogenating agents. Agents in-
cluded in this review include unfractionated heparin, low-molec-
ular-weight heparins, heparinoids, oral vitamin K antagonists and
specific thrombin inhibitors. The control was an inactive inter-
vention, either placebo or no treatment, delivered along with the
standard interventions of the respective healthcare systems.
Heparins are administered parenterally (intravenously or subcuta-
neously) and so have a sufficiently rapid onset to be used in the
acute phase of ischaemic stroke whereas oral anticoagulants, such
as vitamin K antagonists and direct thrombin inhibitors, have a
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slower onset of effect and may be of less use. Unfractionated hep-
arin, a sulphated polysaccharide, acts by binding to antithrom-
bin to inhibit factor Xa and deactivate thrombin. Important side-
effects include thrombocytopenia and osteopenia. Low molecu-
lar weight heparins are depolymerised heparin fragments approx-
imately one third the size of unfractionated heparin and act pri-
marily to inhibit factor Xa. They have a longer half-life, greater
bio-availability andmore predictable anticoagulant effect than un-
fractionated heparin. Heparinoids are glycosaminoglycans whose
components catalyse the effect of heparin co-factor 2 to inhibit
thrombin. All heparins ultimately prevent fibrin formation and
subsequent thrombosis.
How the intervention might work
Theoretically, early use of anticoagulants may, by reducing the
propagation of a thrombus in an intracerebral artery, decrease the
volume of infarcted cerebral tissue and so decrease the neurological
deficit, risk of disability and death. Additionally, anticoagulants
might inhibit the formationof new arterial and venous thromboses
and so reduce the risk of early recurrent thromboembolic stroke,
deep vein thrombosis and pulmonary embolism. However, these
benefits could be offset by the possibility that anticoagulant ther-
apy increases risk of intracranial and extracranial haemorrhage.
Why it is important to do this review
This is an update of a Cochrane review first published in 1995,
and most recently updated in 2008, encompassing all of the ran-
domised trials of anticoagulants versus control in peoplewith acute
presumed or confirmed ischaemic stroke. The aim is to establish
the balance of risk and benefit of early anticoagulation for acute
ischaemic stroke.
O B J E C T I V E S
To assess the effectiveness and safety of early anticoagulation
(within the first 14 days of onset) in people with acute presumed or
confirmed ischaemic stroke. Our hypotheses were that, compared
with a policy of avoiding their use, early anticoagulation would be
associated with:
1. a reduced risk of being dead or dependent in activities of
daily living a few months after stroke onset;
2. a reduced risk of early recurrent ischaemic stroke;
3. an increased risk of symptomatic intracranial and
extracranial haemorrhage; and
4. a reduced risk of deep vein thrombosis and pulmonary
embolism.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought all unconfounded, truly randomised trials in which
early treatment with anticoagulants was compared with control in
people with acute presumed or confirmed ischaemic stroke. People
with ischaemic stroke due to cerebral venous thrombosis were not
specifically included in these trials, and so are not represented in
this review. People with transient ischaemic attacks (TIAs) are also
not included in this review. We did not include trials in which
allocation to treatment or control group was not truly random
or where allocation was not adequately concealed (e.g. allocation
by alternation, date of birth, hospital number, day of the week,
or open random number list), since foreknowledge of treatment
allocation could lead to biased treatment allocation, and thereby
overestimate the treatment effect by up to 30% (Odgaard-Jensen
2011). We included trials if it was unclear whether the method of
randomisation provided adequate concealment of allocation.
Types of participants
This review was confined to the early treatment of acute ischaemic
stroke, and therefore we excluded the following types of trial: those
that randomised participants more than 14 days after stroke on-
set, those that included only people with TIAs, and those that
only included people with intracerebral haemorrhage, confirmed
by appropriate brain imaging before entry. We included trials in
which the pathological type of stroke was not confirmed by scan-
ning before entry, as the majority of such strokes are ischaemic, at
least in the white population (Bamford 1990).
Types of interventions
Anticoagulants are broadly defined as agents that act on the coag-
ulation cascade to exert an anticoagulant effect, excluding throm-
bolytic agents (such as alteplase ) and defibrinogenating agents
(such as ancrod). The use of thrombolytic agents in acute ischaemic
stroke is the subject of a separateCochrane review (Wardlaw 2014),
as is the use of fibrinogen depleting agents (Hao 2012). We in-
cluded the following anticoagulants in this review: subcutaneous
and intravenous standard unfractionated heparin, low-molecular-
weight heparins, subcutaneous and intravenous heparinoids, oral
vitamin K antagonists, factor Xa inhibitors and specific thrombin
inhibitors.
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Types of outcome measures
For each trial, we identified the number of participants originally
randomly allocated to each treatment and control group. In both
groups, we sought outcome information regarding the number of
participants who met the following outcomes.
Primary outcomes
1. Death or dependency (i.e. people who were either dead, or
dependent on help from other people for their activities of daily
living), at least one month after their stroke. This minimum
interval was used to allow time for recovery from the initial
stroke. Comparable definitions of dependency were used in all of
the trials assessed in this review.
Secondary outcomes
1. Participants who died from any cause during the scheduled
treatment period (generally shorter than the scheduled follow-up
period).
2. Participants who died from any cause during the scheduled
follow-up period (greater than one month after their stroke).
3. Participants with objective evidence of deep vein
thrombosis detected by the systematic use of imaging techniques
such as iodine 125 fibrinogen scanning (I-125 scan), ultrasound
of the leg, plethysmography, or X-ray contrast venography in all
participants during the scheduled treatment period and during
scheduled follow up. These methods therefore detected clinically
silent deep vein thrombosis as well as confirming or refuting the
diagnosis in participants with clinical features suggestive of deep
vein thrombosis. The outcome was therefore ’symptomatic or
asymptomatic deep vein thrombosis.’ Screening of participants
by clinical observation alone was not considered adequate.
4. Participants with at least one confirmed symptomatic
pulmonary embolus diagnosed during life, or at autopsy
(symptomatic or not) within the scheduled treatment period and
during scheduled follow-up.
5. Particpants with recurrent stroke during the treatment
period and during follow-up, which was either definitely
ischaemic (haemorrhage excluded by brain imaging or autopsy),
or of unknown type (no brain imaging or autopsy performed).
6. Participants with symptomatic intracranial (intra or
extracerebral) haemorrhage, including symptomatic
haemorrhagic transformation of the cerebral infarct, during the
scheduled treatment period and during follow-up. The
haemorrhage must have been confirmed by appropriate brain
imaging after clinical deterioration, or by autopsy.
7. Participants with any recurrent stroke or symptomatic
intracranial haemorrhage during the treatment period or during
long-term follow up (as previously defined).
8. Participants with any major extracranial haemorrhage
during the scheduled treatment period. The definition of major
haemorrhage was usually taken from the original article but if
none was given it was defined as any fatal bleed, or bleeding
severe enough to require transfusion or operation.
Although we sought trials that reported the primary outcome
(dead or dependent at least one month after stroke), we also in-
cluded data from trials that only reported data on our secondary
outcomes.
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module.We searched for trials in all languages and arranged trans-
lation of relevant papers published in languages other than English
.
Electronic searches
We searched the Cochrane Stroke Group Trials Register (last
searched June 2014) and the following bibliographic databases and
trials registers:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2014 Issue 6) (Appendix 1);
• Cochrane Database of Systematic Reviews (CDSR) (The
Cochrane Library 2014 Issue 6) (Appendix 1);
• Database of Reviews of Effects (DARE) (The Cochrane
Library 2014 Issue 6) (Appendix 1);
• Health Technology Assessment Database (HTA) (The
Cochrane Library 2014 Issue 6) (Appendix 1);
• MEDLINE (Ovid; 2008 to June 2014) (Appendix 2);
• EMBASE (Ovid; 2008 to June 2014) (Appendix 3);
• ClinicalTrials.gov (https://clinicaltrials.gov; searched June
2014) (Appendix 4);
• Internet Stroke Center Stroke Trials Registry (http://
www.strokecenter.org/trials/; searched June 2014) (Appendix 4);
• ISRCTN Registry (http://www.isrctn.com/; searched June
2014) (Appendix 4).
Using a comprehensive search strategy theCochrane StrokeGroup
Trials Search Co-ordinator has already completed a retrospective
search of MEDLINE and EMBASE for all stroke trials to January
2008 and added all relevant trials to the Cochrane Stroke Group
Trials Register. To avoid duplication of effort we have limited the
search of these two databases from January 2008 onwards.
Searching other resources
1. We scanned the reference lists of all relevant papers.
2. For previous versions of this review:
i) we contacted the following anticoagulant
manufacturers in an effort to identify unpublished trials (last
contact 1999): Alfa Wasserman (parnaparin and dermatan
sulphate), Kabi (dalteparin), Knoll (reviparin), Leo (tinzaparin),
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Mediolanum (dermatan sulphate), Mitsubishi Chemical
(argatroban/MD-805), Novo (tinzaparin), Organon
(danaparoid), Rhone-Poulenc Rorer (enoxaparin), Sandoz
(Sandoz LMWH), Sanofi Winthrop (nadroparin and CY 222);
ii) we consulted a comprehensive guide to pharmaceutical
development in the field of stroke (MedStrategy 1995) but have
not updated the search, as relevant trials contained within it are
in the Cochrane Stroke Group Trials Register;
iii) we searched the trials register held by the
Antithrombotic Trialists’ (ATT) Collaboration in August 1998,
but this is no longer available and relevant trials from the register
are now in the Cochrane Stroke Group Trials Register.
Data collection and analysis
For this update EK performed the searches following advice from
Brenda Thomas (Cochrane Stroke Group Trials Search Co-ordi-
nator). EK and PS then independently screened all the titles and
abstracts of the identified references and excluded obviously irrel-
evant studies. EK obtained the full-text articles of the remaining
studies and both EK and PS independently assessed these for in-
clusion or exclusion. We resolved any disagreements by discussion.
Selection of studies
Two review authors (PS & CC, for the trials included in the first
version of this review; PS & Gordon Gubitz for the proceeding
two updates following the original review, Ayeesha Kamal & PS
for the most recent update and PS & EK for this review) inde-
pendently selected trials for inclusion in the review. We resolved
disagreements through discussion. The same two review authors
assessed the methodological quality of each trial.
Data extraction and management
Two review authors independently extracted and cross-checked the
data.We sought data on the number of participants with each out-
come event, by allocated treatment group, irrespective of compli-
ance, and whether or not the participant was subsequently deemed
ineligible or otherwise excluded from treatment or follow-up, to
allow an intention-to-treat (ITT) analysis. We also sought data on
the use of brain imaging prior to randomisation, the delay from
stroke onset to trial entry, the type of patients included, and the
type of anticoagulant regimen used. If any of the above data were
not available in the publications, we sought further information
by correspondence with the trialists.
Assessment of risk of bias in included studies
For the previous versions of this review, two authors assessed the
methodological quality of each trial. We did not use a scoring sys-
tem to assess trial quality, but simply recorded details of randomi-
sation and concealment methods, blinding, if ITT analyses were
possible from the published data (that is, if there were any exclu-
sions from the trial after randomisation) and if any participants
were lost to follow-up. We sought data on the number of par-
ticipants with each outcome event, by allocated treatment group,
irrespective of compliance, and whether or not the participant was
subsequently deemed ineligible or otherwise excluded from treat-
ment or follow-up, to allow an ITT analysis.
Measures of treatment effect
The results reported in the text are odds ratios (OR: that is, the
ratio of the odds of an unfavourable outcome among treatment-
allocated participants to the corresponding odds amongst con-
trols), which we calculated using the Peto fixed-effect method
(APT 1994). We calculated the significance of any differences be-
tween ORs (in relation to subgroup analyses) using a standard
method (Altman 1996). Where relevant, the absolute effects of
treatment on each outcome are expressed as the number needed
to treat to benefit (NNTB) i.e. to avoid one bad outcome event.
For events that are adverse (such as intracranial haemorrhage), this
is calculated as the number needed to treat to harm (NNTH).
To calculate NNTBs or NNTHs, we used the NNT calculator at
http://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp. This ap-
plies the point estimate of relative effect and its 95% confidence
interval (CI), and then calculates theNNTB or NNTH for a spec-
ified control event rate.
Unit of analysis issues
All the included studies were trials in which individuals were
randomised, and follow-up was generally to a prespecified and
fixed time point, and all analyses were by ITT where possible (see
Dealing with missing data). For outcomes where more than one
event could occur during follow-up, such as non-fatal recurrent
stroke, we counted only the first event.
Dealing with missing data
For some outcomes (such as deep vein thrombosis and any in-
tracranial haemorrhage), ITT analyses were not possible because
all participants did not have the relevant investigation performed
to detect the event. In these analyses, we used the number of par-
ticipants in each group who had the appropriate investigation as
the denominator for the main analyses. However, if we found sta-
tistically significant results we also analysed best and worst case
scenarios: the best-case scenario (with regards to treatment) as-
sumed that none of the participants excluded from the analysis
in the treatment group had an adverse outcome, whilst all those
excluded from the control group did, and vice versa for the worst-
case analysis.
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Assessment of heterogeneity
We tested for heterogeneity between trial results with the I² test.
Weused themethoddescribed inBland 2003 to test for interaction
between the effect in a specified subgroup and the overall effect.
Assessment of reporting biases
We sought evidence of publication bias with funnel plots for three
outcomes: deep vein thrombosis, death from all causes within the
scheduled treatment period and death from all causes by the end
of follow-up.
Data synthesis
We used RevMan 2014 for the analyses, in which we grouped to-
gether trials of each type of anticoagulant (e.g. unfractionated hep-
arin, low-molecular-weight heparins, heparinoids, oral vitamin K
antagonists, thrombin inhibitors) to assess whether there were any
significant differences between classes of anticoagulant agent. It
should be noted that this was an indirect rather than a direct ran-
domised comparison.
We also specified the following classification of anticoagulant dos-
ing regimens.
1. Low fixed-dose anticoagulant, that is a dose intended to be
sufficient for the prevention of deep vein thrombosis and
pulmonary embolism.
2. Medium fixed-dose anticoagulant, that is a dose intended to
have effects on the arterial circulation, but not enough to require
monitoring.
3. Adjusted-dose anticoagulant, that is a dose adjusted by
blood testing or body weight to meet a specific target.
Subgroup analysis and investigation of heterogeneity
For this update, we performed subgroup analyses of:
• the type of anticoagulant agent used; and
• the dose of anticoagulant used, applying the classification
above.
Sensitivity analysis
For this update, we performed the following sensitivity analyses,
restricting analyses to:
• trials in which the method of randomisation ensured
adequate concealment of treatment allocation;
• trials in which all participants were recruited within 48
hours of stroke onset; and
• trials except IST 1997, as this trial contained most of the
data for the review.
In the previous version of this review we performed numerous sen-
sitivity analyses to investigate whether the exclusion or inclusion
of trials with particular characteristics would alter the overall con-
clusions. These characteristics included: trials that had intracere-
bral haemorrhages excluded by neuroimaging prior to trial entry,
time from stroke onset (less than 48 hours versus more than 48
hours) to randomisation, concomitant unconfounded treatment
with antiplatelet agents, trials in which stroke was of suspected
cardioembolic origin versus non-cardioembolic origin, and trials
that evaluated different anticoagulant doses. These analyses were
not informative and we have excluded them from this updated
review for brevity and clarity. In future updates of the review, we
do not plan to repeat these analyses unless substantial new trial
data had been added.
R E S U L T S
Description of studies
Results of the search
For this update we searched the Cochrane Stroke Group Trials
Register and performed additional new comprehensive searches of
TheCochrane Library databases,MEDLINEandEMBASE.After
removal of duplicate records we screened the titles and abstracts
of 8913 records from these electronic bibliographic databases and
obtained the full text of six studies, all of whichwe excluded leaving
no new trials for inclusion. The total number of included studies
remains unchanged from the last update at 24 trials. See Figure 1.
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Figure 1. Study flow diagram for 2014 update
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We identified one new ongoing trial from searches of the trials
registers (see Characteristics of ongoing studies).
Included studies
We included 24 trials with a total of 23,748 participants in this re-
view. Summary details of the trials are given in the ’Characteristics
of included studies’ table. Of the 24 included studies, one enrolled
participants within 12 hours of stroke onset (ARGIS-1 2004), two
enrolled participants within 24 hours of stroke onset (FISS-bis
1998; TOAST 1998), 10 enrolled participants within 48 hours of
stroke onset (Cazzato 1989; CESG1983;Duke 1983;Duke 1986;
Elias 1990; FISS 1995; IST 1997; Kwiecinski 1995; McCarthy
1977; McCarthy 1986), and the rest enrolled participants within
14 days. The age of participants in the included studies ranged
from 28 to 92 years. A significant proportion of participants were
over 70 years old. For example, 61% of participants enrolled in
IST 1997 were aged 70 or older.Most trials included slightly more
males than females. Most trials excluded people thought to be at
high risk of bleeding (e.g. clotting disorders, hepatic or renal fail-
ure). In addition, 10 trials excluded people with significant de-
grees of hypertension (generally diastolic pressures greater than
120 mmHg or systolic pressures greater than 180 mmHg), and
nine trials excluded comatose people.
The scheduled period of anticoagulant treatment in the included
trials was one to two weeks in 20 trials and one month in four
trials. The anticoagulants used were:
• standard unfractionated subcutaneous heparin (six trials);
• standard unfractionated intravenous heparin (two trials);
• low-molecular-weight heparins (eight trials: two dalteparin,
two nadroparin, one tinzaparin, one fraxiparin, one parnaparin,
and one CY 222);
• subcutaneous heparinoid (two trials: one danaparoid and
one mesoglycan);
• intravenous heparinoid (one danaparoid trial);
• oral vitamin K antagonists (two trials); and
• thrombin inhibitors (three trials: two MD805 trials, one
argatroban).
In the trials using oral vitamin K antagonists, heparin was given in-
travenously for the first few days to provide rapid anticoagulation
(Marshall 1960; NAT-COOP 1962). Three trials randomised be-
tween two doses of anticoagulant as well as control (FISS 1995;
FISS-bis 1998; IST 1997); for the main analyses in this review we
combined the two anticoagulant groups for these trials.
Fifteen trials routinely performed a CT head scan in all patients
to rule out haemorrhage before randomisation (ARGIS-1 2004;
Cazzato 1989; CESG 1983; Duke 1986; Elias 1990; FISS 1995;
FISS-bis 1998; Kwiecinski 1995; Pambianco 1995; Prins 1989;
Sandset 1990; Tazaki 1986; Tazaki 1992; TOAST 1998; Turpie
1987). Three trials performed CT in most patients (Duke 1983;
IST 1997; Vissinger 1995): eighty-one per cent of participants in
Duke 1983 were scanned; in IST 1997, 67% were scanned be-
fore randomisation, and 29% after randomisation, so that over-
all, 96% of participants were scanned; in Vissinger 1995, 66% of
participants were scanned, and the remainder had cerebral scintig-
raphy to exclude haemorrhage. Three trials performed almost no
CT scans (McCarthy 1977; McCarthy 1986; Pince 1981), and
two trials were undertaken before CT scanning was introduced
(Marshall 1960; NAT-COOP 1962). It is therefore likely that
some people with intracerebral haemorrhage were inadvertently
included in the main analyses of this review. This may have biased
the results against anticoagulation if the risks of anticoagulation
are greater in those with intracerebral haemorrhage, although such
a bias is unlikely given the relatively small numbers of people with
intracerebral haemorrhage involved in these trials, and because
IST 1997 provided well over 80% of the overall data.
Two trials included only participants with presumed cardioem-
bolic stroke (CESG 1983; NAT-COOP 1962). One trial enrolled
a subset of people with atrial fibrillation (IST 1997) and detailed
information on the effect of heparin in this subgroup was reported
in a paper published in 2001 (Saxena 2001).
The duration of follow-up in the trials was generally short, al-
though this was mainly a characteristic of the smaller trials, which
contributed less to the overall analysis. Four trials in which the
primary outcome of interest was deep vein thrombosis did not fol-
low the participants beyond 14 days (Elias 1990;McCarthy 1977;
Pince 1981; Prins 1989), and only 11 trials followed participants
for longer than one month (ARGIS-1 2004; Chaudhary 2002;
Duke 1986; FISS 1995; FISS-bis 1998; IST 1997; Kwiecinski
1995; Marshall 1960; McCarthy 1986; TOAST 1998; Turpie
1987). This lack of long-term follow-up is a weakness of many
of the smaller studies, as a significant proportion of deaths after
onemonth could have been due to stroke-related thromboembolic
events and might therefore have been prevented by early antico-
agulation. Similarly, disability is best assessed when most of the
recovery has taken place (that is between three to six months),
rather than in the first week or so.
Relatively few trials assessed the clinicallymost important outcome
of long-term functional status. Treatments that prevent death from
stroke may lead to survival in a disabled state - an outcome consid-
ered by many to be worse than death. The composite outcome of
’dead or dependent at follow-up’ is therefore the most important
outcome in acute stroke trials. Eight trials assessed this compos-
ite outcome. These trials contain data from well over 90% of the
participants included in this review, and evaluated the outcomes
of death and dependency adequately (ARGIS-1 2004; Cazzato
1989; Chaudhary 2002; FISS 1995; FISS-bis 1998; IST 1997;
Kwiecinski 1995; TOAST 1998). Other important outcomes, in-
cluding recurrent stroke or intracranial haemorrhage, were assessed
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but, once again, only by the more recent trials that included large
numbers of participants. Quality of life assessments were not un-
dertaken in any of these trials.
Excluded studies
We excluded 31 studies for a variety of reasons (see Characteristics
of excluded studies).
Risk of bias in included studies
Randomisation
There was marked variation in the quality of the trials. In 14 trials,
the method of randomisation adequately prevented foreknowl-
edge of treatment allocation. IST 1997 used a central telephone
randomisation service. TOAST 1998 used permuted blocks to
generate a randomisation list controlled by the hospital pharmacy.
Eight trials utilised numbered or coded containers administered
sequentially to enrolled participants (FISS 1995; FISS-bis 1998;
Prins 1989; Sandset 1990;Tazaki 1986;Tazaki 1992;Turpie 1987;
Vissinger 1995). Three trials used random-number tables con-
trolled by an independent party (Cazzato 1989; Duke 1983; Duke
1986). The 2:1 treatment-to-control allocation ratio in Turpie
1987, Tazaki 1986, FISS 1995, and FISS-bis 1998 was deliber-
ate. CESG 1983 used opaque sequentially-numbered envelopes.
The method of randomisation was unclear in nine trials. Six trials
stated that sealed envelopes were used but in five of these it was
not clear whether or not the envelopes were opaque and sequen-
tially numbered (Elias 1990; McCarthy 1977; McCarthy 1986;
NAT-COOP 1962; Pince 1981). In Pambianco 1995 the en-
velopes were not numbered. The exact method of randomisation
was unknown in ARGIS-1 2004, Chaudhary 2002, Kwiecinski
1995, and Marshall 1960.
Allocation
Allocation concealment for the following small trials was unclear:
ARGIS-1 2004, Chaudhary 2002, Elias 1990, Kwiecinski 1995,
Marshall 1960, McCarthy 1977, McCarthy 1986, Pambianco
1995, and Pince 1981. In the remainder we deemed allocation
concealment adequate, with low risk of bias.
Blinding
Adequate blinding may be important to reduce bias in the de-
tection of deep vein thrombosis, pulmonary embolism, symp-
tomatic intracranial haemorrhage, recurrent stroke and functional
outcome. Twelve trials were double-blind, that is treatment allo-
cation was concealed from participants, physicians and outcome
assessors (ARGIS-1 2004; Duke 1983; Duke 1986; FISS 1995;
FISS-bis 1998; Prins 1989; Sandset 1990; Tazaki 1986; Tazaki
1992; TOAST 1998; Turpie 1987; Vissinger 1995), and in two
other trials the assessment of deep vein thrombosis was made
by radiologists blinded to treatment allocation (McCarthy 1977;
McCarthy 1986). Cazzato 1989 had a blinded outcome assessor
only. IST 1997 was not designed as a blinded study. However,
an analysis of 207 participants from the UK enrolled in the IST
pilot study showed that, at the six-month follow-up, the major-
ity of participants could not remember whether or not they had
been treated, and so these participants were effectively ’blinded’
(Lindley 1993). In IST 1997, follow-up data were collected by
self-completed questionnaire mailed to the participant six months
after randomisation, or by telephone interview by a person blinded
to treatment allocation. The remainder of the trials did not appear
to use any form of blinded assessment.
Incomplete outcome data
In total, only 218 participants (0.9% overall) were reported to be
excluded from analysis after randomisation or were lost to follow-
up, with the vast majority of participants enrolled in studies in
which an ITT analysis was performed. However, a number of
participants in the smaller trials that did not report an ITT analysis
may have been omitted from the analysis.
Selective reporting
We were only able to assess this for IST 1997 and did not have
access to the original protocols of the remaining studies. There
was no evidence of reporting bias for IST 1997.
Other potential sources of bias
Long-term use of antiplatelet agents
In trials with follow-up, differences in the long-term use of an-
tiplatelet treatment between the anticoagulant and control groups
after hospital discharge may have biased the results, as antiplatelet
treatment has been shown to reduce the risk of further vascular
events by about 25% (ATC 2002). Aspirin was given to all sur-
vivors in FISS 1995. Long-term treatment with aspirin was en-
couraged, but optional in several other trials, including IST 1997,
FISS-bis 1998 and TOAST 1998. Aspirin (81 mg to 325 mg) was
also used in both arms of the ARGIS-1 2004 trial of the direct
thrombin inhibitor argatroban.
Imbalance at baseline
None of the trials reported significant imbalances in important
baseline prognostic variables, although the small size of many sug-
gests that they might only be ruling out substantial differences.
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Effects of interventions
Outcome 1.1: Dead or dependent at end of follow up
more than one month after randomisation
Eight trials including randomised data from 22,125 participants
(93.2% of participants included in the overall review) evaluated
death and long-term disability. The degree of dependence was de-
termined by noting whether the participants required help from
other people for their activities of daily living at the time of final
follow-up. Treatment with early anticoagulation was not associ-
ated with a significant reduction in the odds of being dead or de-
pendent at final follow up (odds ratio (OR) 0.99; 95% confidence
interval (CI) 0.93 to 1.04, Analysis 1.1). There was, however, sub-
stantial heterogeneity of treatment effect (I² = 47.7%) between
the different regimens included.
Subgroup analyses
By the type of anticoagulant agent used
The heterogeneity in the overall estimate was attributable to the
non-significant trends to benefit associated with low-molecular-
weight heparins and subcutaneous heparinoid regimens, and trend
to harm associated with direct thrombin inhibitor (OR 1.28; 95%
CI 0.62 to 2.62).
By the dose of anticoagulant agent
There was no statistically significant difference in death or depen-
dence at final follow-up between trials in which low fixed-dose
anticoagulants were compared with control (OR 1.00; 95% CI
0.92 to 1.08), or in which medium fixed-dose anticoagulants (OR
0.98; 95% CI 0.91 to 1.06) or adjusted-dose anticoagulants were
compared with control (OR 0.95; 95% CI 0.75 to 1.20).
Sensitivity analyses
Sensitivity analyses restricted to:
• trials in which the method of randomisation ensured
adequate concealment of treatment allocation showed that all of
the trials evaluating death and dependence at final follow-up had
adequate concealment of the randomisation process;
• trials that restricted entry to the study to less than 48 hours
of stroke onset showed that all trials evaluating death or
dependence at final follow-up enrolled participants within 48
hours of stroke onset. Within IST 1997 there was no evidence
that the effect of treatment increased or decreased with
increasing delay to randomisation up to 48 hours;
• trials other than IST 1997 (since it contained most of the
data for the review) showed no apparent difference in the effect
of treatment on death or dependence at final follow-up if data
from IST were included (OR 0.99; 95% CI 0.94 to 1.05) or
excluded (OR 0.92; 95% CI .78 to 1.09).
In a post-hoc sensitivity analysis to assess the impact of duration
of follow-up on the estimate of effect for the primary outcome,
exclusion of the trial with assessment of the primary outcome after
only one month (Cazzato 1989) had no impact on the overall
estimate of effect (OR 0.99; 95% CI 0.94, 1.04) or the degree of
heterogeneity (I² = 55%).
Outcome 1.2: Death from all causes during the
scheduled treatment period
Data from 21 trials, which included randomised data from 22,562
participants (95% of participants included in the review) were
available for this outcome.Anticoagulantswere not associatedwith
a significant reduction in death at the end of the treatment period
(OR 0.99; 95% CI 0.90 to 1.09, Analysis 1.2). There was no
significant heterogeneity (I² = 15.8%).
Outcome 1.3: Death from all causes at final follow-up
more than one month after randomisation
Data were available for 11 trials, which included 22,776 partici-
pants (95.9 % of participants included in the overall review). An-
ticoagulants were not associated with any significant reduction in
the odds of death at final follow-up of greater than one month
(OR 1.05; 95% CI 0.98 to 1.12, I² = 28.5%, Analysis 1.3).
Outcome 1.4: Deep vein thrombosis during the
treatment period
Ten trials, which included randomised data from 916 participants
(only 3.9% of participants included in the overall review), sought
to systematically determine the effect of anticoagulants on the oc-
currence of ’symptomatic or asymptomatic deep vein thrombosis’
at the end of the treatment period, as detected by:
• I-125 fibrinogen scanning (Duke 1983; Elias 1990;
McCarthy 1977; McCarthy 1986; Pince 1981; Prins 1989;
Turpie 1987);
• B-mode and Doppler ultrasound (Pambianco 1995); or
• X-ray contrast venography (Sandset 1990; Vissinger 1995).
Despite the small numbers of participants studied, anticoagulation
was associated with a highly significant reduction in the odds of
deep vein thrombosis (OR 0.21; 95% CI 0.15 to 0.29, Analysis
1.4), although themajority of deep vein thromboses detected were
subclinical and asymptomatic. Assuming a control event rate of
15%, this would be equivalent to an NNTB of 9 (95% CI 9
to 10). To calculate NNTBs for different control event rates, we
used the NNT calculator at http://www.dcn.ed.ac.uk/csrg/entity/
entity˙NNT2.asp. Fifteen participants (10 in the treatment group,
five in the control group) did not have an adequate assessment of
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deep vein thrombosis and therefore we excluded them from this
analysis, however even if we included these participants under a
worst-case scenario the results did not change significantly (OR
0.23).
There was significant heterogeneity between the trial results (I² =
71.5%), which appeared to be due to three trials that did not show
any clear effect of anticoagulation on the odds of deep vein throm-
bosis (Pambianco 1995; Sandset 1990; Vissinger 1995) and two
trials that did (Elias 1990; McCarthy 1986). The three negative
trials were the only ones that did not use I-125 fibrinogen scan-
ning. One used ultrasound assessment (Pambianco 1995) while
the other two used venography (Sandset 1990; Vissinger 1995).
In addition, in one of these trials, participants were randomised
up to 14 days after their initial stroke (Pambianco 1995) whereas
the other trials all randomised participants within seven days. The
two most positive trials had very small numbers of participants,
with the resultant possibility that the results may have been due to
chance. In addition, McCarthy 1986 (the most positive trial) was
poorly concealed, introducing another potential source of bias.
Sensitivity analyses showed that there was no significant difference
in the reduction in deep vein thrombosis from the above result
if the analysis was restricted to trials where the concealment of
allocation was secure (OR 0.45; 95% CI 0.26 to 0.78) or to trials
in which radiographic assessment was blinded (OR 0.21; 95% CI
0.15 to 0.29). One of the trials excluded from this review did pro-
vide data on the numbers of deep vein thromboses in the partici-
pants by allocated treatment group (1/19 heparin, 3/27 placebo),
but inclusion of these results did not significantly alter the analysis
(Dahan 1986). No trials systematically sought to assess deep vein
thrombosis after the end of the treatment period.
Outcome 1.5: Symptomatic pulmonary embolism
during the treatment period
Fourteen trials, which included data from 22,544 participants
(95.7% of participants included in the overall review), assessed
reported fatal and non-fatal symptomatic pulmonary embolism,
but no trial had systematically sought asymptomatic pulmonary
embolism by performing ventilation-perfusion scans in all partic-
ipants at the end of the treatment period. Anticoagulation was
associated with a significant reduction in the odds of pulmonary
embolism (OR 0.60; 95% CI 0.44 to 0.81, I² = 13.7%, Analysis
1.5).
In the trials described, the frequency of pulmonary embolism dur-
ing the treatment period was variable, but quite low (1% in IST
1997 versus 7% in Elias 1990 and Prins 1989). Although not
reported systematically, and thereby potentially under-reported,
the rate of pulmonary embolism in IST 1997 in participants not
receiving heparin was only 0.8%. This observation is supported
by data from prospective hospital-based studies that have reported
symptomatic pulmonary embolism as a complication in between
1% and 3% of patients with acute stroke (Davenport 1996). Ap-
plying the observed odds reduction in pulmonary embolism and
assuming a control event rate of 2%, this effect translated into
an NNTB of 127 (95% CI 91 to 268), although this may be an
underestimate of the reduction in risk due to incomplete ascer-
tainment.
Patients may continue to be at risk of pulmonary embolism af-
ter the early treatment period. This was suggested by data from
three trials that continued to seek events systematically during the
follow-up period (FISS 1995; TOAST 1998; Turpie 1987). Eight
further pulmonary emboli were recorded, six of which were in the
control group. The potential use of antiplatelet or anticoagulant
agents after the trial period may have influenced the results of
several trials (FISS 1995; TOAST 1998; Turpie 1987). One trial,
with an 80% autopsy rate, did show a significant reduction in
the risk of symptomatic and asymptomatic pulmonary embolism
detected at autopsy in the anticoagulation group (7/24 versus 33/
47, OR 0.19; 95% CI 0.07 to 0.52) (McCarthy 1986).
Outcome 1.6: Recurrent ischaemic stroke or
recurrent stroke of unknown pathological type during
the treatment period
Eleven trials, which included 21,605 participants (90.9% of par-
ticipants included in the overall review) systematically sought to
record early recurrent strokes that were definitely ischaemic (CT
scan excluded haemorrhage) or probably ischaemic, that is in
which the cerebral pathology was unknown because a CT scan had
not been performed. Anticoagulation was associated with a sta-
tistically significant reduction in recurrent ischaemic stroke (OR
0.76; 95% CI 0.65 to 0.88, I² = 0, Analysis 1.6) which, assuming
a control event rate of 4%, translated into an NNTB of 108 (95%
CI 74 to 266). Themajority of the data (95%) were obtained from
one trial (IST 1997).
Outcome 1.7: Symptomatic intracranial
haemorrhage during the treatment period
Sixteen trials, which included randomised data from 22,943 par-
ticipants (96.6% of participants included in the overall review)
reported data on symptomatic (fatal and non-fatal) intracranial
haemorrhage confirmed by CT scanning or autopsy. Early antico-
agulation significantly increased symptomatic intracranial haem-
orrhages by more than twofold (OR 2.55; 95% CI 1.95 to 3.33,
I² = 0, Analysis 1.7). Assuming a control event rate of 0.5%, this is
equivalent to a NNTH of 131 (95% CI 88 to 213). The majority
of data (76%) were contributed by one trial (IST 1997).
There was no significant heterogeneity in the excess of haemor-
rhages with different types of heparin. However, within IST 1997,
intracranial haemorrhage significantly increased with increasing
heparin dose. Participants allocated to avoid heparin, low-dose
heparin, andmedium-dose heparin had rates of intracranial haem-
orrhage of 0.3%, 0.7% and 1.8% respectively.
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There is the possibility of some bias within these data, as there
may have been a lower threshold for rescanning participants who
had deteriorated clinically if they were known to be receiving an-
ticoagulants (for example in IST 1997, which was not blinded).
In addition, even in blinded trials, a physician is likely to be un-
blinded if bruising is observed at heparin injection sites. An unbi-
ased assessment of the effect of anticoagulants on the occurrence of
intracranial haemorrhage would come from systematic studies, in
which all participants undergo a CT scan before the beginning of
treatment to exclude haemorrhage, and all survivors have a repeat
CT scan at the end of the scheduled treatment period, regardless
of their clinical status. In such an unbiased assessment, all par-
ticipants who died during the study would also have to undergo
an autopsy. Unfortunately, it is rarely possible to achieve repeat
CT scans in all survivors, or autopsies in all deaths. Five trials in
this review made a systematic attempt to detect both symptomatic
and asymptomatic intracranial haemorrhage in this way (ARGIS-1
2004; CESG 1983; FISS 1995; Prins 1989; Sandset 1990). All
of the confirmed intracranial haemorrhages were intracerebral. In
FISS 1995 the use of systematic CT scanning was introduced dur-
ing the trial and sonot all participantswere eligible for this analysis.
However, the numbers of participants and events in this analysis
were small (symptomatic plus asymptomatic haemorrhages occur-
ring in 20/266 participants (7.5%) allocated anticoagulant versus
27/264 control participants (10.2%)) so the estimate of risk of
’symptomatic plus asymptomatic’ haemorrhage is imprecise (OR
0.76; 95% CI 0.38 to 1.52). In these trials, 25 participants (5%
overall, 15 treated versus 10 control) did not have a repeat CT
scan or autopsy. Including these 25 participants in hypothetical
best and worst-case analyses changed the odds ratio significantly
(OR 0.44 and 1.44 respectively), which suggests that the results
are compatible with either substantial reductions or increases in
the risk of ’symptomatic plus asymptomatic’ intracranial haemor-
rhages with treatment.
Outcome 1.8: Any recurrent stroke or symptomatic
intracranial haemorrhage during the treatment
period and during long-term follow-up
Early anticoagulation reduces the odds of ischaemic stroke but also
increases the odds of symptomatic intracranial haemorrhage. An
outcome that combines these two (without double counting - that
is, each participant is counted only once, even if both events oc-
curred, with the first event being the one which is included) is use-
ful for assessing the net short-term effects of anticoagulants. Eleven
trials, which included randomised data from 21,605 participants
(96.0% of participants included in the overall review), evaluated
the occurrence of ’any recurrent stroke or symptomatic intracra-
nial haemorrhage’ during the treatment period. Anticoagulation
was not associated with a net reduction in the odds of this out-
come (OR 0.97; 95% CI 0.85 to 1.11, I² = 31.3%, Analysis 1.8).
The majority of the data (93.6%) were obtained from IST 1997.
An analysis of the recurrent strokes or intracranial haemorrhages
during the follow-up period could only include data from three
small studies (FISS 1995; Marshall 1960; Turpie 1987). There
were far too few events for a reliable analysis.
Outcome 1.9: Major extracranial haemorrhage
during the treatment period
Eighteen trials, which included randomised data from 22,255
participants (93.7 % of participants included in the overall re-
view), reported data on major extracranial haemorrhage (defined
as bleeding serious enough to cause death or require hospitalisation
or transfusion). Anticoagulation was associated with a significant
three-fold increase in major extracranial haemorrhage (OR 2.99;
95% CI 2.24 to 3.99, I² = 4%, Analysis 1.9). Assuming a control
event rate of 0.4%, this is equivalent to an NNTH of 128 (95%
CI 85 to 204).
Publication bias
To determine whether or not we might have missed an important
number of small negative trials (these are the trials most likely to
remain unpublished) we undertook a funnel plot analysis (Egger
1997). The analyses with the most number of trials included (and
hence the greatest statistical power) were the effects of treatment
on death during the treatment period (Figure 2), death from all
causes at final follow-up (Figure 3) and deep vein thrombosis (
Figure 4). For these outcomes, a plot of the sample size for each
trial versus the odds ratio for that trial showed an approximate
’funnel distribution’ with ’tails’ in both the positive and negative
treatment effect directions (except in the outcome of deep vein
thrombosis) indicating that we were unlikely to have missed a
substantial number of negative trials.
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Figure 2. Death from all causes during the treatment period
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Figure 3. Death from all causes during final follow up
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Figure 4. Funnel plot of deep vein thrombosis during follow-up showing asymmetry
D I S C U S S I O N
The evidence provided in this updated systematic review has not
changed any of the conclusions of the previous review published
in 2008, and can be summarised as follows.
Summary of main results
Net effect of early anticoagulants in acute ischaemic
stroke
Acute stroke treatments should aim to prevent disability as well
as death, lest patients survive their acute stroke only to remain
severely disabled. The currently available evidence from ran-
domised trials indicates that routine early anticoagulation does not
provide any significant net short or long-term reduction in death
or disability. Although early anticoagulation leads to fewer recur-
rent ischaemic strokes (NNTB 108), this benefit is entirely offset
by a similar-sized increase in intracranial haemorrhages (NNTH
131). The net result is no short or long-term benefit.
Hazards of early anticoagulants in acute ischaemic
stroke
In order to be useful, a medical therapy must be safe. The cur-
rent evidence from randomised trials demonstrates a clinically and
statistically significant risk of major intra and extracranial haem-
orrhage with the early use of anticoagulants in people with acute
ischaemic stroke.
Different anticoagulant agents, doses and routes of
administration
The present evidence from randomised trials does not suggest
that any one anticoagulant regimen is superior to any other. Indi-
rect comparisons of unfractionated heparin, low-molecular-weight
heparin, heparinoids and specific thrombin inhibitors have shown
no significant net benefit in terms of reducing death during the
treatment period, or death or dependency after follow-up greater
than one month. Direct comparisons of different anticoagulants
show no clear benefit of heparinoids versus unfractionated heparin
(Sandercock 2008). The available evidence does not support the
routine use of adjusted-dose intravenous heparin (or heparinoid)
regimens, or of more intensive fixed-dose regimens.
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Prevention of deep vein thrombosis and pulmonary
embolism in acute ischaemic stroke with
anticoagulants
In participants with presumed or confirmed ischaemic stroke, allo-
cation to early anticoagulation was associated with a highly signifi-
cant 79%reduction in the odds of deep vein thrombosis during the
treatment period, similar to that seen with the use of prophylactic
heparin in people undergoing different types of surgery (Collins
1988). In this review, the reductions in deep vein thrombosis with
acute anticoagulation were statistically significant, though this es-
timate is based on relatively small numbers of participants, and
most of the deep vein thromboses detected were asymptomatic.
There was also significant heterogeneity in the effects of treatment,
which renders the overall estimate less reliable.
The clinical significance of this reduction depends critically on the
control event rate. In the included studies, there was substantial
variation in the control event rate from 13% in Vissinger 1995 to
73% in McCarthy 1986. The rate will depend on many factors
such as the severity of the stroke, the presence of leg paralysis and
a history of previous deep vein thrombosis (Warlow 2008). The
odds of pulmonary embolism were reduced significantly with the
use of anticoagulants by 40%. In the included trials, pulmonary
embolismwas uncommon, so assuming the 0.8% control rate seen
in the largest trial with the most representative sample of partic-
ipants (IST 1997), the NNTB was 315, though with a perhaps
more realistic control event rate of 2% it would be 127. The over-
all risk of pulmonary embolism appeared to be low, and the ab-
solute benefit was small, and so the apparent reduction in deep
vein thrombosis may have little clinical relevance if there is not a
correspondingly large reduction in pulmonary embolism. How-
ever, there may well have been under-ascertainment of pulmonary
embolism in all of the trials, since data on pulmonary emboli were
not sought systematically. In addition, deep vein thrombosis can
lead to morbidity (such as post-phlebitic leg and varicose ulcers),
but data on these outcomes were not available from the trials. Fi-
nally, it is possible that once anticoagulants are stopped, rebound
thrombosis could occur, and deep vein thromboses may begin to
develop. We were unable to exclude this possibility because no
trials sought data on deep vein thrombosis systematically after the
treatment period.
If anticoagulants result in no net increase or decrease in long-
term death or disability, but do lead to a reduction in the num-
ber of deep vein thromboses and pulmonary emboli (albeit in im-
mobile patients at higher risk), then the benefit of fixed heparin
regimens associated with a low risk of bleeding (for example low
fixed-dose unfractionated or low-molecular weight heparin) may
yet outweigh the increased risk of haemorrhage. A low deep vein
thrombosis risk reduces the justification for unselective throm-
boprophylaxis with heparin. In IST 1997 the frequency of fatal
and non-fatal symptomatic pulmonary embolism (perhaps a sur-
rogate for the occurrence of deep vein thrombosis) was very sim-
ilar among participants allocated low-dose subcutaneous heparin
alone (0.8%) and aspirin alone (0.7%). Aspirin alone may there-
fore be an adequate antithrombotic agent to be used for routine
deep vein thrombosis prophylaxis in some people with acute is-
chaemic stroke, as antiplatelet drugs, when used for prophylaxis
of deep vein thrombosis and pulmonary embolism prophylaxis in
other categories of high-risk patients are of modest benefit (ATC
2002). The recent CLOTS-3 2013 study has demonstrated that
for people with ischaemic and haemorrhagic stroke, intermittent
pneumatic compression reduces the risk of deep vein thrombosis
after stroke, without any increased bleeding risk, and is effective
both in the presence and absence of background heparin therapy.
The effects observed on deep vein thrombosis and pulmonary em-
bolism in the present review indicate theremight be a net benefit of
low-dose heparin regimens among patients who are at high risk of
venous thromboembolism, but at relatively low risk of intracranial
or major extracranial bleeding. PREVAIL 2007 illustrates some of
the difficulty in identifying subgroupswhomight have a favourable
balance of risk and benefit. In that study, although the risk of ve-
nous thromboembolism (VTE) (symptomatic plus asymptomatic)
was significantly lower among participants allocated enoxaparin,
the study could not exclude a 69% increase in the risk of death up
to day 14 and a 134% increase in the risk of intracranial haem-
orrhage with enoxaparin. This was because the event rates for the
more major clinical outcomes were low: among the participants
allocated unfractionated heparin, pulmonary embolism occurred
in 1% and intracerebral haemorrhage in 1%. With such low event
rates, conducting randomised trials large enough to reliably de-
termine the balance of risk and benefit on these major clinical
outcomes is challenging. In conclusion, the data from the present
review were insufficient to reliably identify a subgroup that might
benefit from heparin for thromboprophylaxis.
Overall completeness and applicability of
evidence
This systematic review provides information about the use of an-
ticoagulants in unselected people with ischaemic stroke as well as
limited information about various subgroups. Given that many
of the trials were conducted more than 20 years ago, are these
results still relevant to clinical practice in the 21st century? In
the sense that they represent the totality of evidence comparing
treatment with control, they remain relevant to current practice
in many parts of the world and continue to be cited in stroke
treatment guidelines. The pattern of background treatment has
changed, with many patients now being treated within organised
stroke units (in the developed world at least). This might have an
impact on the absolute risks and benefit of anticoagulation, but is
less likely to influence the estimates of relative effect, and hence -
in our view - the results remain relevant. Anticoagulants are also
sometimes advocated for the treatment of acute carotid dissection
and cerebral venous thrombosis. Separate Cochrane reviews have
been prepared for these topics (Lyrer 2010; Coutinho 2011). We
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were reluctant to pursue further subgroup analysis, since it is haz-
ardous to explore subgroup effects when there is no significant
overall effect of an intervention on major outcomes and we only
had access to major outcomes. A more detailed assessment of the
effects of anticoagulants in other categories of patient (for exam-
ple patients treated within three hours, patients with large-artery
strokes, patients with carotid stenosis) would however, be possible
with an individual patient data meta-analysis.
The stroke patients included in the trials of anticoagulants to pre-
vent deep vein thrombosis generally had quite severe strokes, and
paralysis of one leg (with the attendant high risk of deep vein
thrombosis) was almost invariably present at randomisation. If,
however, one accepts the estimate of treatment effect from these
trials in the 1980s and 1990s, it is then difficult to assess the
extent to which it may be generalisable to clinical practice from
2000 onwards. In current practice, the risk of deep vein throm-
bosis may well be low, since many patients are admitted to stroke
units, receive aspirin, maintain good hydration, and are generally
mobilised early.
With that qualification in mind, the small amounts of (ran-
domised) subgroup data evaluated here do not provide any evi-
dence to support the routine use of anticoagulants in any specific
category of stroke patient.
Quality of the evidence
The bulk of the evidence in this review comes from trials with
adequate allocation concealment, which is a strength. However,
IST 1997 - by far the largest trial - was unblinded - which may well
have led to ascertainment bias especially for the early outcomes.
The final outcome, however, was assessed at a time when patients
could not accurately recall their treatment allocation, so in all
likelihood the assessment of the primary outcome was probably
not materially biased.
Potential biases in the review process
This review is based on an analysis of tabular data, which limits
the extent to which effects in subgroups can be explored. However,
an individual patient data meta-analysis has been performed. The
included trials measured the primary outcome at differing times
after randomisation, ranging from one to six months after ran-
domisation, as we did not have access to individual patient level
data to calculate person-days or hazard ratios. In considering the
impact of differing lengths of follow-up on the primary outcome,
a post hoc-sensitivity analysis excluding the study with less than
three months follow-up did not alter the overall estimate of effect
or reduce the heterogeneity.
Agreements and disagreements with other
studies or reviews
Lederle 2011 is a systematic review of venous thromboembolism
prophylaxis in hospitalised medical patients and those with stroke,
and concluded “Heparin prophylaxis had no significant effect on
mortality, may have reduced PE (pulmonary embolism) in med-
ical patients and all patients combined, and led to more bleed-
ing and major bleeding events, thus resulting in little or no net
benefit. No differences in benefits or harms were found according
to type of heparin used.” Similarly, there was no clear difference
in effects between people with stroke and with other non-surgical
causes for hospital admission. A number of guideline statements
have since been developed; the most recent American Stroke As-
sociation Guidelines (AHAGuidelines 2012) include two specific
recommendations that are supported by the evidence provided in
this systematic review. These are as follows.
• Urgent anticoagulation, with the goal of preventing early
recurrent stroke, halting neurological worsening, or improving
outcomes after acute ischaemic stroke, is not recommended for
treatment of patients with acute ischaemic stroke.
• At present, the usefulness of argatroban or other thrombin
inhibitors for treatment of patients with acute ischaemic stroke is
not well established.
An individual patient data meta-analysis of the large trials of hep-
arin in acute ischaemic stroke was recently able to explore sub-
group effects in greater detail, with the aim of identifying the sub-
group of patients most likely to derive net benefit from heparin.
However, the authors concluded: “There was no evidence that pa-
tients with ischaemic stroke who were at higher risk of thrombotic
events or lower risk of haemorrhagic events benefited from hep-
arins. We were, therefore, unable to define a targeted approach to
select the patients who would benefit from treatment with early
anticoagulant therapy.” (Whiteley 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence from this systematic review indicates that, compared
with control, the types of anticoagulants tested in people with
acute ischaemic stroke have no effect in terms of death in the short
term, or death or dependency after follow-up of at least onemonth.
A reduction in recurrent ischaemic stroke during the treatment
period is exactly offset by an increase in intracranial haemorrhage.
Although anticoagulants decrease deep vein thrombosis and pul-
monary embolus, these benefits are once again offset by similar-
sized increases in extracranial haemorrhage.
The data do not support the routine use of early high-dose in-
travenous or subcutaneous anticoagulants in any form for peo-
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ple with acute ischaemic stroke. Low-dose subcutaneous regimens
will prevent deep vein thrombosis, but with a small but definite
increased risk of major haemorrhage. It may therefore be advisable
to consider safer alternatives in immobile patients (such as aspirin,
compression stockings, or early mobilisation).
The data reviewed from trials comparing these agents with control
do not support the use of low-molecular-weight heparins, hepari-
noids or thrombin inhibitors in the treatment of acute ischaemic
stroke.
The analysis performed did not identify any category of patient
where there was clear net benefit. Clinicians who feel compelled to
use early anticoagulants for specific categories of patients follow-
ing acute ischaemic stroke should weigh any potential theoretical
benefits with the known risk of bleeding. Aspirin is an effective an-
tithrombotic alternative to anticoagulation that is safe when used
in the acute phase of ischaemic stroke.
Implications for research
This review has not provided reliable evidence on a number of
important categories of patient with acute cerebrovascular disease
who might plausibly derive net benefit from early anticoagulation
(very recent transient ischaemic attacks (within hours or days of
onset), crescendo transient ischaemic attacks and progressing is-
chaemic stroke are a few examples) and further trials targeted at
these groups (perhaps with new agents) may be warranted. The
choice of comparator agent against which to test any anticoagulant
will depend on a number of factors, but further trials comparing
anticoagulants against control seem unlikely.
Those clinicians whowish to continue to use intensive intravenous
dose-adjusted heparin regimens routinely to treat specific cate-
gories of stroke patient should provide convincing evidence from
new randomised controlled trials to support such practices.
This review has not provided clear evidence about the optimum
antithrombotic regimen for the prevention of deep vein thrombo-
sis and pulmonary embolism in stroke patients. Aspirin alone, low-
dose subcutaneous heparin, and the use of graded compression
stockings are all promising possibilities, but a very large scale ran-
domised trial with several tens of thousands of participants would
be required to determine which (or which combination) has the
most favourable balance of risk and benefit on overall clinical out-
come.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ARGIS-1 2004
Methods C = randomisation not described
Patient, doctor and assessments blinded
Exclusions during the trial: none
Losses to FU: 5 participants
Participants North America
171 participants
Mean age 65 years
100% CT before entry
Mild to moderate ischaemic stroke NIHSS 7 to 22
Less than 12 hours since onset
Interventions Rx: argatroban 100 mcg/kg bolus, followed by low-dose arm 1 mcg/kg/min or high-dose
arm 3 mcg/kg/min for 5 days versus placebo




Barthel, NIHSS, MRS at 90 days
Notes Ex: age > 85
BP: > 220/130
FU: 30 days, 90 days
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Cazzato 1989
Methods C = random number table controlled by doctor not involved in treatment
Outcome assessor blind
Exclusions during trial: none
Losses to FU: none
Participants Italy
57 participants
Mean age 68 years
49% male
100% CT before entry
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Cazzato 1989 (Continued)
Ischaemic stroke
Less than 48 hours since stroke onset
Interventions Rx: mesoglycan (heparinoid) 50 mg 8 hourly im for 5 days, then 144 mg/day orally for 25
days
Control: no treatment
All participants received dexamethasone iv
Duration: 30 days
Outcomes Death plus cause of death
Functional outcome (OHS 3, 4, 5 = dependent)
PE (symptomatic plus autopsy in 9/10 deaths)






Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
CESG 1983
Methods C = sealed envelopes (opaque and sequentially numbered)
Non-blind
Exclusions during trial: none
Losses to FU: none
Participants North America
45 participants
42 to 83 years
58% male
100% CT before entry
Cardioembolic stroke
Less than 48 hours since stroke onset
Interventions Rx: heparin iv (continuous, APTT 1.5 to 2.5) +/- coumadin
Control: no treatment
Duration: 10 days
Outcomes Death plus cause of death
Intracranial haemorrhage (systematic CT on day 4 to 10)
Recurrent stroke
Major extracranial haemorrhage
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CESG 1983 (Continued)
Notes Ex: BP > 180/115, bleeding risk
FU: 14 days
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Chaudhary 2002
Methods C = randomisation not described
Assessment not blinded
Exclusions during trial: none




100% CT before entry
Acute stroke - time not otherwise defined
Interventions Rx: parnaparin 0.3 ml sc bid for 10 days versus placebo
Outcomes Death and Barthel Index at 3 months
Notes Ex: CT with ICH, coagulopathy
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Duke 1983
Methods C = random number list controlled by pharmacy
Doctor, patient, and assessor blind
Exclusions during trial: none





81% CT before entry
’Partial stable’ ischaemic stroke < 48 hours since stroke onset
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Duke 1983 (Continued)




DVT (systematic I-125 scan)
Intracranial haemorrhage (symptomatic)
Extracranial haemorrhage
Notes Ex: BP > 120 diastolic, bleeding risk
FU: 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Duke 1986
Methods C = random number list controlled by pharmacy
Doctor, patient, and assessor blind
Exclusions during trial: none
Losses to FU: 3 participants (number in each group unknown)
Participants Canada
225 participants
Mean age 67 years
63% male
100% CT before entry
’Partial stable’ non-cardioembolic ischaemic stroke < 48hrs since stroke onset
Interventions Rx: heparin iv (continuous, APTT 50 to 70 seconds)
Control: placebo
Duration: 7 days
Antiplatelet therapy during follow up not reported
Outcomes Death but not cause of death
Functional outcome (measured but not reported)
Intracranial haemorrhage (symptomatic)
Notes Ex: BP > 110 diastolic, coma
FU: 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
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Duke 1986 (Continued)
Allocation concealment (selection bias) Low risk A - Adequate
Elias 1990
Methods C = sealed envelopes (? opaque and sequentially numbered)
Non-blind
Exclusions during trial: none
Losses to FU: 2 in Rx group
Participants Europe
30 participants
Mean age 68 years
57% male
100% CT before entry
Ischaemic stroke with immobility
Less than 48 hours since stroke onset
Interventions Rx: CY 222 (LMWH) 15,000 anti-Xa units sc 24 hourly
Control: no treatment
Duration: 14 days
Outcomes Death plus cause of death
DVT (systematic I-125 scan, venography 50%)
Major extracranial haemorrhage
Notes Ex: BP > 220/120, coma
FU: 14 days
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
FISS 1995
Methods C = sequentially numbered boxes containing identical syringes
Doctor, patient, and assessor blind
Exclusions during trial: 4 in Rx group (survival status known for all except one)
Losses to FU: 2 in Rx group
Participants Hong Kong
312 participants
Mean age 67 years
58% male
100% CT before entry
Ischaemic stroke with motor deficit
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FISS 1995 (Continued)
Less than 48 hours since stroke onset




All surviving participants received aspirin 100 mg/day after 10 days
Outcomes Death plus cause of death
Functional outcome (dependency assessed using International Stroke Trial simple ques-
tions)
PE (symptomatic)








Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
FISS-bis 1998
Methods C = sequentially numbered boxes
Doctor, patient and assessor blind
Exclusions during trial: unknown





100% CT before entry
Ischaemic stroke with motor deficit < 24 hours since stroke onset




Functional Outcome (Barthel Index score < 85 = dependent)
Intracerebral haemorrhage (symptomatic CT)
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FISS-bis 1998 (Continued)
Notes Ex: mild stroke, coma
FU: 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
IST 1997
Methods C = telephone randomisation
Unblinded; dependency assessment mainly blinded
Exclusions during trial: none




61% > 70 years
54% male
67% CT prior to randomisation, 29% CT after randomisation
Ischaemic stroke < 48 hours since stroke onset
Interventions Rx: sc heparin (5000 IU or 12,500 IU 12 hourly), aspirin 300mg, both, or neither (factorial
design)
Duration: 14 days or until discharge from hospital
Outcomes Death
Functional outcome (validated simple questions)
Recurrent stroke
PE
Intracranial haemorrhage (symptomatic CT)
Extracranial haemorrhage
Notes Ex: small likelihood of worthwhile benefit; high risk of adverse effect (e.g. hypersensitivity
of aspirin, recent GI bleed or peptic ulcer disease, already on long-term anticoagulation)
FU: 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
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Kwiecinski 1995
Methods C = unknown
Blinding not stated
Exclusions during trial: unknown
Losses to FU: unknown
Participants Poland
120 participants
Mean age 57 years
65% male
100% CT before entry
Enrolled less than 48 hours after ischaemic stroke
Interventions Rx: fraxiparin (LMWH)





Intracerebral haemorrhage (symptomatic CT)
Symptomatic DVT and PE during treatment period
Notes Ex: > 65 years, comatose, severe comorbidity, uncontrolled hypertension
FU: 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Marshall 1960
Methods C = unknown
Non-blind
Exclusions during trial: none
Losses to FU: none
Participants United Kingdom
51 participants
30 to 70 years
47% male
No CT, 100% LP plus angiography
Non-cardioembolic ischaemic stroke < 72 hours since stroke onset
Interventions Rx: heparin iv (3 doses of 12,500 IU), then phenindione orally 12 hourly (PT 2 to 3)
Control: no treatment
Duration: 21 days
No antiplatelet therapy during follow up
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Marshall 1960 (Continued)
Outcomes Death but not cause of death
Fatal intracranial haemorrhage (autopsies in 8/9 deaths)
Recurrent stroke
Major extracranial haemorrhage
Notes Ex: bleeding risk
FU: 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
McCarthy 1977
Methods C = sealed envelopes (? opaque and sequentially numbered)
DVT assessment blind
Exclusions during trial: none
Losses to FU: none
Participants United Kingdom
32 participants
Mean age 78 years
34% male
No CT, 100% LP before entry
Any stroke with no blood in CSF
Less than 48 hours since stroke onset
Interventions Rx: heparin 5000 IU sc 8 hourly
Control: no treatment
Duration: 14 days
Outcomes Death but not cause of death
DVT (systematic I-125 scan)
Notes Ex: BP > 120 diastolic, bleeding risk
FU: 1 month
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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McCarthy 1986
Methods C = sealed envelopes (? opaque and sequentially numbered)
DVT assessment blind
Exclusions during trial: none
Losses to FU: none
Participants United Kingdom
305 participants
Mean age 76 years
43% male
No CT before entry
All strokes (10% haemorrhagic on autopsy)
Less than 48 hours since stroke onset
Interventions Rx: heparin 5000 IU sc 8 hourly
Control: no treatment
Duration: 14 days
Antiplatelet therapy during follow up not reported
Outcomes Death but not cause of death
DVT (systematic I-125 scan)
Notes Ex: BP > 120 diastolic, bleeding risk
FU: 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
NAT-COOP 1962
Methods C = sealed envelopes (? opaque and sequentially numbered)
Patient only blind
Exclusions during trial: none
Losses to FU: none
Participants USA
30 participants
26 older than 55 years
53% male
No CT, 100% LP before entry
Cardioembolic stroke
Less than 2 weeks since stroke onset
Interventions Rx: heparin 50 mg iv 4 hourly, then dicumarol (oral anticoagulant; PT 15 to 20%)
Control: placebo
Duration: 1 month
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NAT-COOP 1962 (Continued)
Outcomes Death plus cause of death
Recurrent stroke
Extracranial haemorrhage
Notes Ex: bleeding risk
FU: 1 year but only complete FU for all patients up to 1 month
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Pambianco 1995
Methods C = sealed, opaque but not sequentially numbered envelopes
Non-blind
Exclusions during trial: none
Losses to FU: none
Participants USA
131 participants
Mean age 71 years
50% male
100% CT before entry
Ischaemic stroke with severe leg weakness
Less than 14 days since stroke onset
Interventions Rx: heparin 5000 IU sc 8 hourly, with dose adjustment to maintain PT 30 to 40 seconds
Control: no treatment
Duration: 28 days
Outcomes Death plus cause of death
DVT (systematic B mode and Doppler ultrasound)
PE
Major extracranial haemorrhage
Notes Ex: bleeding risk, active cancer
FU: 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Pince 1981
Methods C = sealed envelopes (? opaque and sequentially numbered)
Non-blind
Exclusions during trial: Rx 0, control 4 participants (2 with intracranial haemorrhage)
Losses to FU: none
Participants France
80 participants
30 to 92 years
62% male
No CT, 100% LP before entry
Ischaemic stroke affecting the leg
Less than 7 days since stroke onset (89% < 48 hours)
Interventions Rx: heparin 5000 IU sc 8 hourly
Control: no treatment
Duration: 10 days
Outcomes Death but not cause of death
DVT (systematic I-125 scan)
PE
Major extracranial haemorrhage
Notes Ex: bleeding risk
FU: 10 days
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Prins 1989
Methods C = sequentially numbered identical syringes
Double-blind
Exclusions during trial: none
Losses to FU: none
Participants Netherlands
60 participants
78% > 70 years
52% male
100% CT before entry
Ischaemic stroke less than 72 hours since stroke onset
Interventions Rx: dalteparin (LMWH, Kabi 2165) 2500 anti-Xa units sc 12 hourly
Control: placebo
Duration: 14 days
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Prins 1989 (Continued)
Outcomes Death plus cause of death
DVT (systematic I-125 scan with venography)
PE





Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Sandset 1990
Methods C = sequentially numbered identical ampoules
Doctor, patient and assessor blind
Exclusions during trial: none
Losses to FU: none
Participants Norway
103 participants
47 to 90 years
45% male
100% CT before entry
Non-cardioembolic ischaemic stroke
Less than 72 hours since stroke onset
Interventions Rx: dalteparin (LMWH, Kabi 2165) 3000 to 5500 anti-Xa U sc 24 hourly
Control: placebo
Duration: 14 days
Outcomes Death plus cause of death
DVT (systematic venography or B mode ultrasound)
PE (symptomatic plus autopsy in 5/6 deaths)
Intracranial haemorrhage (systematic CT)
Major extracranial haemorrhage
Notes Ex: BP > 120 diastolic, coma, bleeding risk
FU: 28 days
Risk of bias
Bias Authors’ judgement Support for judgement
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Sandset 1990 (Continued)
Allocation concealment (selection bias) Low risk A - Adequate
Tazaki 1986
Methods C = numbered or coded containers administered sequentially to enrolled participants
Doctor, patient and assessor blind
Exclusions during trial: none
Losses to FU: none
Participants Japanese
156 participants
68% > 60 years
66% male
100% CT before entry
Ischaemic stroke within 7 to 10 days of stroke onset
Interventions Rx: MD805 (thrombin inhibitor) 60 mg/day versus 30 mg/day continuous iv for 2 days;
then 20 mg 12 hourly iv for 5 days
Control: placebo
All patients received glycerol 500 mg/day
Duration: 7 days
Outcomes Death
Functional outcome (graded on ADL-type scale)




Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Tazaki 1992
Methods C = numbered or coded containers administered sequentially to enrolled patients
Doctor, patient and assessor blind
Exclusions during trial: none
Losses to FU: none
Participants Japanese
138 participants
Mean age 68 years
64% male
100% CT before entry
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Tazaki 1992 (Continued)
Ischaemic stroke within 5 to 7 days of stroke onset
Interventions Rx: MD805 (thrombin inhibitor) 60 mg/days for two days (continuous iv), then MD805
20 mg 12 hourly for 5 days (iv)
Control: placebo




Intracranial haemorrhage (symptomatic CT)
Notes Ex: decreased level of consciousness, bleeding risk, pregnancy, age > 85 years, significant
medical disease (cardiac, hepatic, renal)
FU: 1 month
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
TOAST 1998
Methods C = permuted blocks with randomly ordered sizes of 6, 6, and 4; randomisation lists
pharmacy controlled
Doctor, patient and assessor blind
Exclusions during trial: none
Losses to FU: 25 participants (11 treatment, 14 control)
Participants United States
1281 participants
Mean age 65 years
61% male
100% CT before entry
Ischaemic stroke > 1 hour and < 24 hours from symptom onset with estimated pre-stroke
Barthel Index or 12 or more
Interventions Rx: danaparoid (heparinoidOrg 10172) bolus followed by continuous infusion tomaintain
blood anti-Xa levels of 0.6 to 0.8
Control: placebo
Duration: 7 days
Outcomes Functional outcome: Barthel Index < 85, NIHSS, Glasgow Outcome Scale
Recurrent stroke
Intracranial haemorrhage (symptomatic CT)
Extracranial haemorrhage
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TOAST 1998 (Continued)
Notes Ex: Age < 18 or > 85, women of childbearing potential, severe stroke (NIHSS score > 15),
weight less than 125 pounds
FU: 7 days and 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Turpie 1987
Methods C = sequentially numbered identical containers
Double-blind
Exclusions during trial: none
Losses to FU: none
Participants Canada
75 participants
28 to 90 years
53% male
100% CT before entry
Non-cardioembolic ischaemic stroke with immobility
Less than 7 days since stroke onset
Interventions Rx: danaparoid (heparinoid Org 10172) 750 anti-Xa units sc 12 hourly
Control: placebo
Duration: 14 days or prior discharge
Antiplatelet therapy during follow up not reported
Outcomes Death plus cause of death
DVT (systematic I-125 scan + plethysmography with venography)
PE (symptomatic)
Intracranial haemorrhage (symptomatic CT)
Extracranial haemorrhage
Recurrent stroke
Notes Ex: bleeding risk
FU: 3 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
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Vissinger 1995
Methods C = coded containers administered sequentially to enrolled participants
Doctor, patient and assessor blind
Exclusions during trial: none
Losses to FU: 31/50 participants lost to 6-month follow up
Participants Denmark
50 participants
Mean age 71.8 years
58% male
66% CT before entry - haemorrhage excluded in remainder by cerebral scintigraphy
Non-embolic ischaemic stroke with motor deficit < 24 hours since stroke onset
Interventions Rx: tinzaparin (LMWH) 3500 anti-Xa IU sc once daily
Control: placebo




Notes Exclusion criteria: < 50 years old, hypertension (BP > 200/120 mmHg), coma, aphasia,
bleeding risk, oral anticoagulant treatment, severe hepatic or renal disease, clinical suspicion
of DVT or PE
FU: 12 to 14 days and 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
ADL: activities of daily living
APTT: activated partial thromboplastin time
bid: twice a day
BP: blood pressure
C: concealment of allocation
CSF: cerebrospinal fluid
CT: computerised tomography









MRS: modified Rankin Scale
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NIHSS: National Institutes of Health Stroke Scale





Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bradshaw 1975 Non-random: allocation by odd/even year of birth
Camerlingo 2005 Confounded by the use of low-dose unfractionated heparin in control group
Carter 1961 Non-random: alternate allocation
COU 9116 Participants randomised after 14 days of stroke onset
Czechanowski 1981 Confounded with dihydroergotamine
Dahan 1986 Not all participants were stroke patients: individual patient data for stroke patients not available
Dan 2001 Methods of randomisation unclear; no clinically relevant outcomes reported
Dehen 1994 Control group received a low-molecular-weight heparin i.e. dermatan sulphate plus placebo versus low-molec-
ular-weight heparin plus placebo
Enger 1965 Time from stroke to treatment unclear
Eriksson 1983 Non-random: allocation by month of admission
Gelmers 1980 Non-random: alternate allocation
Kang 2010 No clinical outcome data
Kario 1995 No clinically relevant outcomes reported
Kobayashi 1997 No clinically relevant outcomes reported
Lee 1994 Confounded with urokinase
Lee 2008 Comparison of 2 anticoagulant regimens
Luo 2013 Comparison of 2 anticoagulant regimens
McCarthy 1993 Data not available despite repeated contact with authors
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(Continued)
McDevitt 1959 Time from stroke to treatment unclear
Meredit 2009 Comparison of 2 anticoagulant regimens
Rosin 1994 Data not available despite repeated contact with authors
Shi 2004 No clinically relevant outcomes reported
Stiekema 1988 No control group: dose-finding trial
Tan 1998 Not randomised; no clinically relevant outcomes reported
Thygesen 1964 Non-random allocation
Tomek 2011 Comparison of 2 anticoagulant regimens
Tsuchiya 1989 Confounded with urokinase
Tsuchiya 1990 Confounded with urokinase
VA Study 1961 Treatment started acutely in only 50% and unable to get individual patient data for just these participants
Zhang 2005 Not clearly randomised
Zhao 2014 Anticoagulant versus antiplatelet regimen
Characteristics of ongoing studies [ordered by study ID]
Nosal 2014
Trial name or title Safety and efficacy of heparin and nadroparin in the acute phase of ischemic stroke (Heparinas)
Methods Double Blind (patient, caregiver, investigator, outcomes assessor)
Participants 18 to 80 years old
Estimated 150 participants
Slovakia
Interventions Rx: heparin iv/nadroparin sc/placebo iv immediately
Followed by nadroparin sc at 24 hours
Duration of anticoagulation: 72 hours
Outcomes Safety: incidence of intracranial haemorrhage
Efficacy: level of improvement measured by mRS, and NIHSS
Starting date May 2013
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Nosal 2014 (Continued)
Contact information Vladimir Nosal, MD, PhD, vnosal@gmail.com
Notes ClinicalTrials.gov Identifier: NCT01862978
iv: intravenous
mRS: modified Rankin Scale
NIHSS: National Institutes of Health Stroke Scale
sc: subcutaneous
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D A T A A N D A N A L Y S E S
Comparison 1. Anticoagulant versus control in acute presumed ischaemic stroke




participants Statistical method Effect size
1 Dead or dependent at end of
follow up (if > 1 month)
8 22125 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.93, 1.04]
1.1 Unfractionated heparin
(subcutaneous) versus control
1 19435 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.00 [0.94, 1.06]
1.2 Low-molecular-weight
heparin versus control
4 1228 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.82 [0.64, 1.04]
1.3 Heparinoid
(subcutaneous) versus control
1 57 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.81 [0.29, 2.27]
1.4 Heparinoid (intravenous)
versus control
1 1276 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.92 [0.72, 1.19]
1.5 Direct thrombin inhibitor
versus control (intravenous)
1 129 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.28 [0.62, 2.62]
2 Death from all causes during
treatment period
21 22562 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.90, 1.09]
2.1 Unfractionated heparin
(subcutaneous) versus control
5 19743 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.88, 1.07]
2.2 Unfractionated heparin
(intravenous) versus control
2 270 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.63 [0.11, 3.71]
2.3 Low-molecular-weight
heparin versus control
6 585 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.60 [0.87, 2.95]
2.4 Heparinoid
(subcutaneous) versus control
2 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.03 [0.32, 3.37]
2.5 Heparinoid (intravenous)
versus control
1 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.31 [0.55, 3.11]
2.6 Oral vitamin K antagonist
versus control
2 81 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.27 [0.46, 3.48]
2.7 Thrombin inhibitor versus
control
3 470 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.60 [0.95, 7.09]
3 Death from all causes at final
follow up (if > 1 month)
11 22776 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.98, 1.12]
3.1 Unfractionated heparin
(subcutaneous) versus control
2 19740 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.98, 1.12]
3.2 Unfractionated heparin
(intravenous) versus control
1 225 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.26 [0.99, 5.19]
3.3 Low-molecular-weight
heparin versus control
4 1228 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.74, 1.32]
3.4 Heparinoid
(subcutaneous) versus control
1 75 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.44 [0.09, 2.05]
3.5 Heparinoid (intravenous)
versus control
1 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.09 [0.69, 1.72]
3.6 Oral vitamin K antagonist
versus control
1 51 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.35, 3.76]
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3.7 Direct thrombin inhibitor
(intravenous) versus control
1 176 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.79 [0.71, 4.53]
4 Deep vein thrombosis during
treatment period
10 916 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.21 [0.15, 0.29]
4.1 Unfractionated heparin
(subcutaneous) versus control
5 609 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.16 [0.11, 0.24]
4.2 Low-molecular-weight
heparin versus control
4 232 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.41 [0.23, 0.73]
4.3 Heparinoid
(subcutaneous) versus control




14 22544 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.60 [0.44, 0.81]
5.1 Unfractionated heparin
(subcutaneous) versus control
3 19645 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.49, 0.96]
5.2 Unfractionated heparin
(intravenous) versus control
1 45 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Low-molecular-weight
heparin versus control
7 1441 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.31 [0.15, 0.64]
5.4 Heparinoid
(subcutaneous) versus control
2 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.66 [0.15, 386.16]
5.5 Heparinoid (intravenous)
versus control
1 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.00, 6.70]
6 Recurrent ischaemic or unknown
stroke during treatment period
11 21605 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.65, 0.88]
6.1 Unfractionated heparin
(subcutaneous) versus control
2 19566 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.65, 0.89]
6.2 Unfractionated heparin
(intravenous) versus control
1 45 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.11 [0.01, 1.85]
6.3 Low-molecular-weight
heparin versus control
2 362 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.47 [0.14, 1.58]
6.4 Heparinoid
(subcutaneous) versus control
2 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.48 [0.07, 286.49]
6.5 Heparinoid (intravenous)
versus control
1 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.34, 2.82]
6.6 Oral vitamin K antagonist
versus control
2 81 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.65 [0.11, 3.90]
6.7 Thrombin inhibitor versus
control




16 22943 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.55 [1.95, 3.33]
7.1 Unfractionated heparin
(subcutaneous) versus control
3 19631 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.69 [1.97, 3.67]
7.2 Unfractionated heparin
(intravenous) versus control
2 270 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Low-molecular-weight
heparin versus control
6 1321 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.61 [0.80, 3.22]
7.4 Heparinoid
(subcutaneous) versus control
1 75 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.48 [0.07, 286.49]
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7.5 Heparinoid (intravenous)
versus control
1 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.91 [0.98, 8.69]
7.6 Oral vitamin K antagonist
versus control
1 51 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.78 [0.37, 21.00]
7.7 Thrombin inhibitor versus
control
1 138 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.39 [0.15, 372.38]
7.8 Direct thrombin inhibitor
(intravenous) versus control
1 176 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.60 [0.70, 30.35]
8 Any recurrent stroke or
symptomatic intracranial
haemorrhage during treatment
period or follow up (> 1
month)
11 21605 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.85, 1.11]
8.1 Unfractionated heparin
(subcutaneous) versus control
2 19566 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.84, 1.11]
8.2 Unfractionated heparin
(intravenous) versus control
1 45 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.11 [0.01, 1.85]
8.3 Low-molecular-weight
heparin versus control
2 362 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.39 [0.12, 1.26]
8.4 Heparinoid
(subcutaneous) versus control
2 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.57 [0.24, 88.28]
8.5 Heparinoid (intravenous)
versus control
1 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.43 [0.67, 3.07]
8.6 Oral vitamin K antagonist
versus control
2 81 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.24 [0.32, 4.88]
8.7 Thrombin inhibitor versus
stroke
1 138 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.61 [0.78, 74.40]
9 Major extracranial haemorrhage
during treatment period
18 22255 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.99 [2.24, 3.99]
9.1 Unfractionated heparin
(subcutaneous) versus control
4 19711 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.06 [2.25, 4.15]
9.2 Unfractionated heparin
(intravenous) versus control
1 45 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Low-molecular-weight
heparin versus control
5 535 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.48 [0.03, 9.05]
9.4 Heparinoid
(subcutaneous) versus control
2 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.66 [0.15, 386.16]
9.5 Heparinoid (intravenous)
versus control
1 1281 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.31 [1.20, 9.15]
9.6 Oral vitamin K antagonist
versus control
2 81 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.00, 6.82]
9.7 Thrombin inhibitor versus
control
2 294 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.8 Direct thrombin inhibitor
(intravenous) versus control
1 176 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Subgroup analysis by
anticoagulant dose: effect on
death or dependency
8 22127 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.93, 1.04]
10.1 Adjusted full-dose
intravenous anticoagulant
2 1409 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.75, 1.20]
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10.2 Medium fixed-dose
anticoagulant
4 10361 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.91, 1.06]
10.3 Low fixed-dose
anticoagulant
5 10357 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.00 [0.92, 1.08]
Analysis 1.1. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 1
Dead or dependent at end of follow up (if > 1 month).
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 1 Dead or dependent at end of follow up (if > 1 month)





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
IST 1997 6063/9717 6062/9718 89.2 % 1.00 [ 0.94, 1.06 ]
Subtotal (95% CI) 9717 9718 89.2 % 1.00 [ 0.94, 1.06 ]
Total events: 6063 (Treatment), 6062 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 Low-molecular-weight heparin versus control
Chaudhary 2002 1/15 6/15 0.1 % 0.17 [ 0.03, 0.87 ]
FISS 1995 100/207 68/105 1.4 % 0.52 [ 0.32, 0.83 ]
FISS-bis 1998 300/516 142/250 3.2 % 1.06 [ 0.78, 1.43 ]
Kwiecinski 1995 19/62 21/58 0.5 % 0.78 [ 0.37, 1.66 ]
Subtotal (95% CI) 800 428 5.2 % 0.82 [ 0.64, 1.04 ]
Total events: 420 (Treatment), 237 (Control)
Heterogeneity: Chi2 = 9.92, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 1.64 (P = 0.10)
3 Heparinoid (subcutaneous) versus control
Cazzato 1989 13/28 15/29 0.3 % 0.81 [ 0.29, 2.27 ]
Subtotal (95% CI) 28 29 0.3 % 0.81 [ 0.29, 2.27 ]
Total events: 13 (Treatment), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
4 Heparinoid (intravenous) versus control
TOAST 1998 159/641 167/635 4.7 % 0.92 [ 0.72, 1.19 ]
Subtotal (95% CI) 641 635 4.7 % 0.92 [ 0.72, 1.19 ]
Total events: 159 (Treatment), 167 (Control)
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
5 Direct thrombin inhibitor versus control (intravenous)
ARGIS-1 2004 43/83 21/46 0.6 % 1.28 [ 0.62, 2.62 ]
Subtotal (95% CI) 83 46 0.6 % 1.28 [ 0.62, 2.62 ]
Total events: 43 (Treatment), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 11269 10856 100.0 % 0.99 [ 0.93, 1.04 ]
Total events: 6698 (Treatment), 6502 (Control)
Heterogeneity: Chi2 = 13.37, df = 7 (P = 0.06); I2 =48%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 3.45, df = 4 (P = 0.48), I2 =0.0%
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Analysis 1.2. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 2
Death from all causes during treatment period.
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 2 Death from all causes during treatment period





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
Duke 1983 0/35 1/30 0.1 % 0.11 [ 0.00, 5.84 ]
IST 1997 876/9717 905/9718 92.7 % 0.96 [ 0.88, 1.06 ]
McCarthy 1977 3/16 5/16 0.4 % 0.52 [ 0.11, 2.53 ]
Pambianco 1995 0/64 0/67 Not estimable
Pince 1981 10/40 5/40 0.7 % 2.25 [ 0.74, 6.86 ]
Subtotal (95% CI) 9872 9871 93.8 % 0.97 [ 0.88, 1.07 ]
Total events: 889 (Treatment), 916 (Control)
Heterogeneity: Chi2 = 3.91, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.67 (P = 0.50)
2 Unfractionated heparin (intravenous) versus control
CESG 1983 0/24 2/21 0.1 % 0.11 [ 0.01, 1.85 ]
Duke 1986 2/112 1/113 0.2 % 1.98 [ 0.20, 19.20 ]
Subtotal (95% CI) 136 134 0.3 % 0.63 [ 0.11, 3.71 ]
Total events: 2 (Treatment), 3 (Control)
Heterogeneity: Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.50 (P = 0.61)
3 Low-molecular-weight heparin versus control
Chaudhary 2002 0/15 0/15 Not estimable
Elias 1990 3/15 3/15 0.3 % 1.00 [ 0.17, 5.81 ]
FISS 1995 15/207 8/105 1.1 % 0.95 [ 0.39, 2.32 ]
Prins 1989 9/30 4/30 0.6 % 2.63 [ 0.78, 8.88 ]
Sandset 1990 5/52 1/51 0.3 % 3.98 [ 0.77, 20.55 ]
Vissinger 1995 1/20 0/30 0.1 % 12.18 [ 0.22, 665.65 ]
Subtotal (95% CI) 339 246 2.4 % 1.60 [ 0.87, 2.95 ]
Total events: 33 (Treatment), 16 (Control)
Heterogeneity: Chi2 = 4.40, df = 4 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.50 (P = 0.13)
4 Heparinoid (subcutaneous) versus control
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Cazzato 1989 6/28 4/29 0.5 % 1.68 [ 0.43, 6.50 ]
Turpie 1987 1/50 2/25 0.1 % 0.21 [ 0.02, 2.44 ]
Subtotal (95% CI) 78 54 0.6 % 1.03 [ 0.32, 3.37 ]
Total events: 7 (Treatment), 6 (Control)
Heterogeneity: Chi2 = 2.10, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.05 (P = 0.96)
5 Heparinoid (intravenous) versus control
TOAST 1998 12/646 9/635 1.2 % 1.31 [ 0.55, 3.11 ]
Subtotal (95% CI) 646 635 1.2 % 1.31 [ 0.55, 3.11 ]
Total events: 12 (Treatment), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
6 Oral vitamin K antagonist versus control
Marshall 1960 6/26 3/25 0.4 % 2.11 [ 0.51, 8.79 ]
NAT-COOP 1962 6/15 7/15 0.4 % 0.77 [ 0.19, 3.18 ]
Subtotal (95% CI) 41 40 0.9 % 1.27 [ 0.46, 3.48 ]
Total events: 12 (Treatment), 10 (Control)
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
7 Thrombin inhibitor versus control
ARGIS-1 2004 6/118 1/58 0.3 % 2.40 [ 0.48, 11.93 ]
Tazaki 1986 3/104 1/52 0.2 % 1.47 [ 0.18, 11.96 ]
Tazaki 1992 5/69 1/69 0.3 % 3.99 [ 0.78, 20.37 ]
Subtotal (95% CI) 291 179 0.9 % 2.60 [ 0.95, 7.09 ]
Total events: 14 (Treatment), 3 (Control)
Heterogeneity: Chi2 = 0.56, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.062)
Total (95% CI) 11403 11159 100.0 % 0.99 [ 0.90, 1.09 ]
Total events: 969 (Treatment), 963 (Control)
Heterogeneity: Chi2 = 21.38, df = 18 (P = 0.26); I2 =16%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Chi2 = 7.01, df = 6 (P = 0.32), I2 =14%
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Analysis 1.3. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 3
Death from all causes at final follow up (if > 1 month).
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 3 Death from all causes at final follow up (if > 1 month)





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
IST 1997 2165/9717 2076/9718 89.8 % 1.06 [ 0.99, 1.13 ]
McCarthy 1986 31/144 53/161 1.6 % 0.57 [ 0.34, 0.94 ]
Subtotal (95% CI) 9861 9879 91.4 % 1.04 [ 0.98, 1.12 ]
Total events: 2196 (Treatment), 2129 (Control)
Heterogeneity: Chi2 = 5.80, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 1.24 (P = 0.22)
2 Unfractionated heparin (intravenous) versus control
Duke 1986 17/112 8/113 0.6 % 2.26 [ 0.99, 5.19 ]
Subtotal (95% CI) 112 113 0.6 % 2.26 [ 0.99, 5.19 ]
Total events: 17 (Treatment), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
3 Low-molecular-weight heparin versus control
Chaudhary 2002 0/15 0/15 Not estimable
FISS 1995 32/207 20/105 1.1 % 0.77 [ 0.41, 1.45 ]
FISS-bis 1998 146/516 68/250 3.7 % 1.06 [ 0.75, 1.48 ]
Kwiecinski 1995 6/62 5/58 0.3 % 1.13 [ 0.33, 3.90 ]
Subtotal (95% CI) 800 428 5.0 % 0.99 [ 0.74, 1.32 ]
Total events: 184 (Treatment), 93 (Control)
Heterogeneity: Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
4 Heparinoid (subcutaneous) versus control
Turpie 1987 4/50 4/25 0.2 % 0.44 [ 0.09, 2.05 ]
Subtotal (95% CI) 50 25 0.2 % 0.44 [ 0.09, 2.05 ]
Total events: 4 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
5 Heparinoid (intravenous) versus control
TOAST 1998 42/646 38/635 2.0 % 1.09 [ 0.69, 1.72 ]
Subtotal (95% CI) 646 635 2.0 % 1.09 [ 0.69, 1.72 ]
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 42 (Treatment), 38 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
6 Oral vitamin K antagonist versus control
Marshall 1960 8/26 7/25 0.3 % 1.14 [ 0.35, 3.76 ]
Subtotal (95% CI) 26 25 0.3 % 1.14 [ 0.35, 3.76 ]
Total events: 8 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
7 Direct thrombin inhibitor (intravenous) versus control
ARGIS-1 2004 18/118 5/58 0.5 % 1.79 [ 0.71, 4.53 ]
Subtotal (95% CI) 118 58 0.5 % 1.79 [ 0.71, 4.53 ]
Total events: 18 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 11613 11163 100.0 % 1.05 [ 0.98, 1.12 ]
Total events: 2469 (Treatment), 2284 (Control)
Heterogeneity: Chi2 = 12.58, df = 9 (P = 0.18); I2 =28%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 6.01, df = 6 (P = 0.42), I2 =0%
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Analysis 1.4. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 4
Deep vein thrombosis during treatment period.
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 4 Deep vein thrombosis during treatment period





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
McCarthy 1977 2/16 12/16 5.0 % 0.09 [ 0.02, 0.34 ]
Duke 1983 0/35 3/30 1.8 % 0.11 [ 0.01, 1.07 ]
McCarthy 1986 32/144 117/161 46.8 % 0.13 [ 0.09, 0.21 ]
Pince 1981 7/40 14/36 9.4 % 0.35 [ 0.13, 0.95 ]
Pambianco 1995 3/64 3/67 3.5 % 1.05 [ 0.20, 5.37 ]
Subtotal (95% CI) 299 310 66.5 % 0.16 [ 0.11, 0.24 ]
Total events: 44 (Treatment), 149 (Control)
Heterogeneity: Chi2 = 8.93, df = 4 (P = 0.06); I2 =55%
Test for overall effect: Z = 9.40 (P < 0.00001)
2 Low-molecular-weight heparin versus control
Elias 1990 0/15 12/15 4.6 % 0.04 [ 0.01, 0.17 ]
Prins 1989 6/27 15/30 8.3 % 0.31 [ 0.11, 0.90 ]
Vissinger 1995 2/20 4/30 3.2 % 0.73 [ 0.13, 4.11 ]
Sandset 1990 15/45 17/50 13.1 % 0.97 [ 0.42, 2.27 ]
Subtotal (95% CI) 107 125 29.1 % 0.41 [ 0.23, 0.73 ]
Total events: 23 (Treatment), 48 (Control)
Heterogeneity: Chi2 = 14.79, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 3.05 (P = 0.0023)
3 Heparinoid (subcutaneous) versus control
Turpie 1987 2/50 7/25 4.4 % 0.11 [ 0.02, 0.46 ]
Subtotal (95% CI) 50 25 4.4 % 0.11 [ 0.02, 0.46 ]
Total events: 2 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.99 (P = 0.0027)
Total (95% CI) 456 460 100.0 % 0.21 [ 0.15, 0.29 ]
Total events: 69 (Treatment), 204 (Control)
Heterogeneity: Chi2 = 31.61, df = 9 (P = 0.00023); I2 =72%
Test for overall effect: Z = 9.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.88, df = 2 (P = 0.02), I2 =75%
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Analysis 1.5. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 5
Symptomatic pulmonary embolism during treatment period.
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 5 Symptomatic pulmonary embolism during treatment period





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
IST 1997 53/9716 81/9718 79.0 % 0.66 [ 0.47, 0.92 ]
Pambianco 1995 2/64 1/67 1.8 % 2.06 [ 0.21, 20.19 ]
Pince 1981 1/40 0/40 0.6 % 7.39 [ 0.15, 372.38 ]
Subtotal (95% CI) 9820 9825 81.4 % 0.69 [ 0.49, 0.96 ]
Total events: 56 (Treatment), 82 (Control)
Heterogeneity: Chi2 = 2.37, df = 2 (P = 0.31); I2 =16%
Test for overall effect: Z = 2.21 (P = 0.027)
2 Unfractionated heparin (intravenous) versus control
CESG 1983 0/24 0/21 Not estimable
Subtotal (95% CI) 24 21 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Low-molecular-weight heparin versus control
Elias 1990 0/15 1/15 0.6 % 0.14 [ 0.00, 6.82 ]
FISS 1995 0/207 0/105 Not estimable
FISS-bis 1998 9/516 14/250 11.7 % 0.27 [ 0.11, 0.65 ]
Kwiecinski 1995 0/62 2/58 1.2 % 0.12 [ 0.01, 2.01 ]
Prins 1989 1/30 2/30 1.7 % 0.50 [ 0.05, 5.02 ]
Sandset 1990 2/52 2/51 2.3 % 0.98 [ 0.13, 7.17 ]
Vissinger 1995 0/20 0/30 Not estimable
Subtotal (95% CI) 902 539 17.5 % 0.31 [ 0.15, 0.64 ]
Total events: 12 (Treatment), 21 (Control)
Heterogeneity: Chi2 = 2.15, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.15 (P = 0.0016)
4 Heparinoid (subcutaneous) versus control
Cazzato 1989 1/28 0/29 0.6 % 7.66 [ 0.15, 386.16 ]
Turpie 1987 0/50 0/25 Not estimable
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Subtotal (95% CI) 78 54 0.6 % 7.66 [ 0.15, 386.16 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
5 Heparinoid (intravenous) versus control
TOAST 1998 0/646 1/635 0.6 % 0.13 [ 0.00, 6.70 ]
Subtotal (95% CI) 646 635 0.6 % 0.13 [ 0.00, 6.70 ]
Total events: 0 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Total (95% CI) 11470 11074 100.0 % 0.60 [ 0.44, 0.81 ]
Total events: 69 (Treatment), 104 (Control)
Heterogeneity: Chi2 = 10.43, df = 9 (P = 0.32); I2 =14%
Test for overall effect: Z = 3.31 (P = 0.00092)
Test for subgroup differences: Chi2 = 5.91, df = 3 (P = 0.12), I2 =49%
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Analysis 1.6. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 6
Recurrent ischaemic or unknown stroke during treatment period.
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 6 Recurrent ischaemic or unknown stroke during treatment period





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
IST 1997 283/9717 370/9718 95.1 % 0.76 [ 0.65, 0.89 ]
Pambianco 1995 0/64 0/67 Not estimable
Subtotal (95% CI) 9781 9785 95.1 % 0.76 [ 0.65, 0.89 ]
Total events: 283 (Treatment), 370 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00054)
2 Unfractionated heparin (intravenous) versus control
CESG 1983 0/24 2/21 0.3 % 0.11 [ 0.01, 1.85 ]
Subtotal (95% CI) 24 21 0.3 % 0.11 [ 0.01, 1.85 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
3 Low-molecular-weight heparin versus control
FISS 1995 6/207 6/105 1.6 % 0.47 [ 0.14, 1.58 ]
Vissinger 1995 0/20 0/30 Not estimable
Subtotal (95% CI) 227 135 1.6 % 0.47 [ 0.14, 1.58 ]
Total events: 6 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
4 Heparinoid (subcutaneous) versus control
Cazzato 1989 0/28 0/29 Not estimable
Turpie 1987 1/50 0/25 0.1 % 4.48 [ 0.07, 286.49 ]
Subtotal (95% CI) 78 54 0.1 % 4.48 [ 0.07, 286.49 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
5 Heparinoid (intravenous) versus control
TOAST 1998 7/646 7/635 2.1 % 0.98 [ 0.34, 2.82 ]
Subtotal (95% CI) 646 635 2.1 % 0.98 [ 0.34, 2.82 ]
Total events: 7 (Treatment), 7 (Control)
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
6 Oral vitamin K antagonist versus control
Marshall 1960 0/26 2/25 0.3 % 0.12 [ 0.01, 2.05 ]
NAT-COOP 1962 2/15 1/15 0.4 % 2.05 [ 0.20, 21.36 ]
Subtotal (95% CI) 41 40 0.7 % 0.65 [ 0.11, 3.90 ]
Total events: 2 (Treatment), 3 (Control)
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.48 (P = 0.63)
7 Thrombin inhibitor versus control
Tazaki 1992 1/69 0/69 0.2 % 7.39 [ 0.15, 372.38 ]
Subtotal (95% CI) 69 69 0.2 % 7.39 [ 0.15, 372.38 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 10866 10739 100.0 % 0.76 [ 0.65, 0.88 ]
Total events: 300 (Treatment), 388 (Control)
Heterogeneity: Chi2 = 6.90, df = 7 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Chi2 = 4.65, df = 6 (P = 0.59), I2 =0.0%
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Analysis 1.7. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 7
Symptomatic intracranial haemorrhage during treatment period.
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 7 Symptomatic intracranial haemorrhage during treatment period





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
Duke 1983 0/35 0/30 Not estimable
IST 1997 120/9717 41/9718 74.5 % 2.69 [ 1.97, 3.67 ]
Pambianco 1995 0/64 0/67 Not estimable
Subtotal (95% CI) 9816 9815 74.5 % 2.69 [ 1.97, 3.67 ]
Total events: 120 (Treatment), 41 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.25 (P < 0.00001)
2 Unfractionated heparin (intravenous) versus control
CESG 1983 0/24 0/21 Not estimable
Duke 1986 0/112 0/113 Not estimable
Subtotal (95% CI) 136 134 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Low-molecular-weight heparin versus control
Chaudhary 2002 0/15 0/15 Not estimable
FISS 1995 0/207 1/105 0.4 % 0.05 [ 0.00, 3.24 ]
FISS-bis 1998 25/516 7/250 12.6 % 1.67 [ 0.78, 3.54 ]
Prins 1989 1/30 0/30 0.5 % 7.39 [ 0.15, 372.38 ]
Sandset 1990 2/52 1/51 1.4 % 1.94 [ 0.20, 19.03 ]
Vissinger 1995 0/20 0/30 Not estimable
Subtotal (95% CI) 840 481 14.9 % 1.61 [ 0.80, 3.22 ]
Total events: 28 (Treatment), 9 (Control)
Heterogeneity: Chi2 = 3.27, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 1.33 (P = 0.18)
4 Heparinoid (subcutaneous) versus control
Turpie 1987 1/50 0/25 0.4 % 4.48 [ 0.07, 286.49 ]
Subtotal (95% CI) 50 25 0.4 % 4.48 [ 0.07, 286.49 ]
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
5 Heparinoid (intravenous) versus control
TOAST 1998 10/646 3/635 6.0 % 2.91 [ 0.98, 8.69 ]
Subtotal (95% CI) 646 635 6.0 % 2.91 [ 0.98, 8.69 ]
Total events: 10 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
6 Oral vitamin K antagonist versus control
Marshall 1960 3/26 1/25 1.8 % 2.78 [ 0.37, 21.00 ]
Subtotal (95% CI) 26 25 1.8 % 2.78 [ 0.37, 21.00 ]
Total events: 3 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
7 Thrombin inhibitor versus control
Tazaki 1992 1/69 0/69 0.5 % 7.39 [ 0.15, 372.38 ]
Subtotal (95% CI) 69 69 0.5 % 7.39 [ 0.15, 372.38 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
8 Direct thrombin inhibitor (intravenous) versus control
ARGIS-1 2004 5/118 0/58 2.0 % 4.60 [ 0.70, 30.35 ]
Subtotal (95% CI) 118 58 2.0 % 4.60 [ 0.70, 30.35 ]
Total events: 5 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Total (95% CI) 11701 11242 100.0 % 2.55 [ 1.95, 3.33 ]
Total events: 168 (Treatment), 54 (Control)
Heterogeneity: Chi2 = 5.88, df = 9 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 6.85 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.61, df = 6 (P = 0.86), I2 =0.0%
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Analysis 1.8. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 8
Any recurrent stroke or symptomatic intracranial haemorrhage during treatment period or follow up (> 1
month).
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 8 Any recurrent stroke or symptomatic intracranial haemorrhage during treatment period or follow up (> 1 month)





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
IST 1997 396/9717 411/9718 93.6 % 0.96 [ 0.84, 1.11 ]
Pambianco 1995 0/64 0/67 Not estimable
Subtotal (95% CI) 9781 9785 93.6 % 0.96 [ 0.84, 1.11 ]
Total events: 396 (Treatment), 411 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Unfractionated heparin (intravenous) versus control
CESG 1983 0/24 2/21 0.2 % 0.11 [ 0.01, 1.85 ]
Subtotal (95% CI) 24 21 0.2 % 0.11 [ 0.01, 1.85 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
3 Low-molecular-weight heparin versus control
FISS 1995 6/207 7/105 1.4 % 0.39 [ 0.12, 1.26 ]
Vissinger 1995 0/20 0/30 Not estimable
Subtotal (95% CI) 227 135 1.4 % 0.39 [ 0.12, 1.26 ]
Total events: 6 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
4 Heparinoid (subcutaneous) versus control
Cazzato 1989 0/28 0/29 Not estimable
Turpie 1987 2/50 0/25 0.2 % 4.57 [ 0.24, 88.28 ]
Subtotal (95% CI) 78 54 0.2 % 4.57 [ 0.24, 88.28 ]
Total events: 2 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
5 Heparinoid (intravenous) versus control
TOAST 1998 16/646 11/635 3.2 % 1.43 [ 0.67, 3.07 ]
Subtotal (95% CI) 646 635 3.2 % 1.43 [ 0.67, 3.07 ]
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 16 (Treatment), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
6 Oral vitamin K antagonist versus control
Marshall 1960 3/26 3/25 0.7 % 0.96 [ 0.18, 5.17 ]
NAT-COOP 1962 2/15 1/15 0.3 % 2.05 [ 0.20, 21.36 ]
Subtotal (95% CI) 41 40 1.0 % 1.24 [ 0.32, 4.88 ]
Total events: 5 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
7 Thrombin inhibitor versus stroke
Tazaki 1992 3/69 0/69 0.4 % 7.61 [ 0.78, 74.40 ]
Subtotal (95% CI) 69 69 0.4 % 7.61 [ 0.78, 74.40 ]
Total events: 3 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
Total (95% CI) 10866 10739 100.0 % 0.97 [ 0.85, 1.11 ]
Total events: 428 (Treatment), 435 (Control)
Heterogeneity: Chi2 = 10.19, df = 7 (P = 0.18); I2 =31%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 9.93, df = 6 (P = 0.13), I2 =40%
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Analysis 1.9. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome 9
Major extracranial haemorrhage during treatment period.
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 9 Major extracranial haemorrhage during treatment period





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Unfractionated heparin (subcutaneous) versus control
Duke 1983 0/35 0/30 Not estimable
IST 1997 129/9717 37/9718 89.8 % 3.06 [ 2.25, 4.15 ]
Pambianco 1995 0/64 0/67 Not estimable
Pince 1981 0/40 0/40 Not estimable
Subtotal (95% CI) 9856 9855 89.8 % 3.06 [ 2.25, 4.15 ]
Total events: 129 (Treatment), 37 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.17 (P < 0.00001)
2 Unfractionated heparin (intravenous) versus control
CESG 1983 0/24 0/21 Not estimable
Subtotal (95% CI) 24 21 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Low-molecular-weight heparin versus control
Chaudhary 2002 0/15 0/15 Not estimable
Elias 1990 0/15 0/15 Not estimable
FISS 1995 1/207 1/105 1.0 % 0.48 [ 0.03, 9.05 ]
Prins 1989 0/30 0/30 Not estimable
Sandset 1990 0/52 0/51 Not estimable
Subtotal (95% CI) 319 216 1.0 % 0.48 [ 0.03, 9.05 ]
Total events: 1 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
4 Heparinoid (subcutaneous) versus control
Cazzato 1989 1/28 0/29 0.5 % 7.66 [ 0.15, 386.16 ]
Turpie 1987 0/50 0/25 Not estimable
Subtotal (95% CI) 78 54 0.5 % 7.66 [ 0.15, 386.16 ]
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
5 Heparinoid (intravenous) versus control
TOAST 1998 12/646 3/635 8.1 % 3.31 [ 1.20, 9.15 ]
Subtotal (95% CI) 646 635 8.1 % 3.31 [ 1.20, 9.15 ]
Total events: 12 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
6 Oral vitamin K antagonist versus control
Marshall 1960 0/26 0/25 Not estimable
NAT-COOP 1962 0/15 1/15 0.5 % 0.14 [ 0.00, 6.82 ]
Subtotal (95% CI) 41 40 0.5 % 0.14 [ 0.00, 6.82 ]
Total events: 0 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
7 Thrombin inhibitor versus control
Tazaki 1986 0/104 0/52 Not estimable
Tazaki 1992 0/69 0/69 Not estimable
Subtotal (95% CI) 173 121 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Direct thrombin inhibitor (intravenous) versus control
ARGIS-1 2004 0/118 0/58 Not estimable
Subtotal (95% CI) 118 58 Not estimable
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 11255 11000 100.0 % 2.99 [ 2.24, 3.99 ]
Total events: 143 (Treatment), 42 (Control)
Heterogeneity: Chi2 = 4.17, df = 4 (P = 0.38); I2 =4%
Test for overall effect: Z = 7.41 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.17, df = 4 (P = 0.38), I2 =4%
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Analysis 1.10. Comparison 1 Anticoagulant versus control in acute presumed ischaemic stroke, Outcome
10 Subgroup analysis by anticoagulant dose: effect on death or dependency.
Review: Anticoagulants for acute ischaemic stroke
Comparison: 1 Anticoagulant versus control in acute presumed ischaemic stroke
Outcome: 10 Subgroup analysis by anticoagulant dose: effect on death or dependency





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adjusted full-dose intravenous anticoagulant
ARGIS-1 2004 58/86 30/47 0.5 % 1.17 [ 0.56, 2.48 ]
TOAST 1998 159/641 167/635 4.8 % 0.92 [ 0.72, 1.19 ]
Subtotal (95% CI) 727 682 5.3 % 0.95 [ 0.75, 1.20 ]
Total events: 217 (Treatment), 197 (Control)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.66)
2 Medium fixed-dose anticoagulant
FISS 1995 46/105 34/52 0.7 % 0.42 [ 0.22, 0.82 ]
FISS-bis 1998 145/245 71/124 1.6 % 1.08 [ 0.70, 1.68 ]
IST 1997 3022/4856 3031/4859 44.6 % 0.99 [ 0.92, 1.08 ]
Kwiecinski 1995 19/62 21/58 0.5 % 0.78 [ 0.37, 1.66 ]
Subtotal (95% CI) 5268 5093 47.4 % 0.98 [ 0.91, 1.06 ]
Total events: 3232 (Treatment), 3157 (Control)
Heterogeneity: Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.45 (P = 0.65)
3 Low fixed-dose anticoagulant
Cazzato 1989 13/28 15/29 0.3 % 0.81 [ 0.29, 2.27 ]
Chaudhary 2002 1/15 6/15 0.1 % 0.17 [ 0.03, 0.87 ]
FISS 1995 54/102 34/52 0.7 % 0.60 [ 0.31, 1.18 ]
FISS-bis 1998 155/271 71/125 1.6 % 1.02 [ 0.66, 1.56 ]
IST 1997 3041/4861 3031/4859 44.6 % 1.01 [ 0.93, 1.09 ]
Subtotal (95% CI) 5277 5080 47.3 % 1.00 [ 0.92, 1.08 ]
Total events: 3264 (Treatment), 3157 (Control)
Heterogeneity: Chi2 = 6.85, df = 4 (P = 0.14); I2 =42%
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI) 11272 10855 100.0 % 0.99 [ 0.93, 1.04 ]
Total events: 6713 (Treatment), 6511 (Control)
Heterogeneity: Chi2 = 14.17, df = 10 (P = 0.17); I2 =29%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 0.17, df = 2 (P = 0.92), I2 =0.0%
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A P P E N D I C E S
Appendix 1. Cochrane Library Databases (CENTRAL, CDSR, DARE, HTA)
#1 [mh ˆ“cerebrovascular disorders”] or [mh ˆ“basal ganglia cerebrovascular disease”] or [mh ˆ“brain ischemia”] or [mh “brain infarction”]
or [mh ˆ“hypoxia-ischemia, brain”] or [mh ˆ“carotid artery diseases”] or [mh ˆ“carotid artery thrombosis”] or [mh ˆ“carotid artery,
internal, dissection”] or [mh ˆ“intracranial arterial diseases”] or [mh ˆ“cerebral arterial diseases”] or [mh ˆ“infarction, anterior cerebral
artery”] or [mh ˆ“infarction, middle cerebral artery”] or [mh ˆ“infarction, posterior cerebral artery”] or [mh “intracranial embolism
and thrombosis”] or [mh stroke] or [mh ˆ“vertebral artery dissection”]
#2 isch*mi* near/5 (stroke* or apoplex* or cerebral next vasc* or cerebrovasc* or cva):ti,ab
#3 (brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or
middle next cerebr* or mca* or “anterior circulation” or “basilar artery” or “vertebral artery”) near/5 (isch*mi* or infarct* or thrombo*
or emboli* or occlus* or hypoxi*):ti,ab
#4 #1 or #2 or #3
#5 [mh anticoagulants]
#6 [mh “Blood coagulation factors”/AI,DE] or [mh “Blood coagulation”/AI,DE]
#7 (anticoagul* or antithromb*):ti,ab
#8 [mh ˆWarfarin] or [mh ˆ4-hydroxycoumarins] or [mh âcenocoumarol] or [mh ˆcoumarins] or [mh ˆdicumarol] or [mh ˆ“ethyl
biscoumacetate”] or [mh ˆphenindione] or [mh ˆphenprocoumon]
#9 [mh “Vitamin K”/AI]
#10 (warfarin* or coumadin* or coumarin* or cumarin* or phenprocoum* or phenprocum* or dicoumar* or dicumar* or acenocoumar*
or acenocumar* or fluindione or phenindione or clorindione or diphenadione or “ethyl biscoumacetate”):ti,ab
#11 (Vitamin next K next antagonist* or VKA or VKAs or “antivitamin K”):ti,ab
#12 [mh antithrombins] or [mh ˆ“hirudin therapy”] or [mh ˆthrombin/AI]
#13 ((direct* near/5 thrombin near/5 inhib*) or DTI or DTIs):ti,ab
#14 (argatroban or MD805 or “MD-805” or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or
napsagatran or bivalirudin or lepirudin or hirudin* or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin
or odiparcil):ti,ab
#15 [mh ˆ“factor Xa”/AI]
#16 ((“factor Xa” or “factor 10a” or fXa or “autoprothrombin c” or thrombokinase) near/5 inhib*):ti,ab
#17 (activated near/5 (“factor X” or “factor 10”) near/5 inhib*):ti,ab
#18 xabans:ti,ab
#19 (antistasin or apixaban or betrixaban or “du 176b” or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or
rivaroxaban or yagin or “ym 150” or ym150 or LY517717 or darexaban or edoxaban or SSR126517E or fidexaban or idrabiotaparinux
or letaxaban or tanogitran or taxexaban):ti,ab
#20 [mh ˆheparin] or [mh “heparin, low-molecular-weight”] or [mh ˆheparinoids]
#21 (heparin* or lmwh* or enoxaparin* or glycosaminoglycan* or nadroparin* or mesoglycan* or tedelparin* or certoparin or tinzaparin
or parnaparin or dalteparin or reviparin or fraxiparin* or danaparoid or lomoparan or “org 10172” or mesoglycan or pentosan next
polysul* or sp54 or “sp-54” or cy222 or “cy-222” or cy216 or “cy-216” or dermatan next sul* or heparan next sul*):ti,ab
#22 {or #5-#21}
#23 #4 and #22
#24 atrial fibrillation:ti
#25 #23 not #24
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Appendix 2. MEDLINE (Ovid)
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or brain ischemia/ or exp brain infarction/ or hypoxia-ischemia,
brain/ or carotid artery diseases/ or carotid artery thrombosis/ or carotid artery, internal, dissection/ or intracranial arterial diseases/ or
cerebral arterial diseases/ or infarction, anterior cerebral artery/ or infarction, middle cerebral artery/ or infarction, posterior cerebral
artery/ or exp “intracranial embolism and thrombosis”/ or exp stroke/ or vertebral artery dissection/
2. (isch?emi$ adj5 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$
or occlus$ or hypoxi$)).tw.
4. 1 or 2 or 3
5. exp anticoagulants/
6. exp Blood coagulation factors/ai, de or exp Blood coagulation/ai, de
7. (anticoagul$ or antithromb$).tw.
8. Warfarin/ or 4-hydroxycoumarins/ or acenocoumarol/ or coumarins/ or dicumarol/ or ethyl biscoumacetate/ or phenindione/ or
phenprocoumon/
9. exp Vitamin K/ai
10. (warfarin$ or coumadin$ or coumarin$ or cumarin$ or phenprocoum$ or phenprocum$ or dicoumar$ or dicumar$ or aceno-
coumar$ or acenocumar$ or fluindione or phenindione or clorindione or diphenadione or ethyl biscoumacetate).tw,nm.
11. (Vitamin K antagonist$ or VKA or VKAs or antivitamin K).tw.
12. exp antithrombins/ or hirudin therapy/ or thrombin/ai
13. ((direct$ adj5 thrombin adj5 inhib$) or DTI$1).tw.
14. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or
napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin
or odiparcil).tw,nm.
15. factor Xa/ai
16. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5 inhib$).tw.
17. (activated adj5 (factor X or factor 10) adj5 inhib$).tw.
18. xabans.tw.
19. (antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or
rivaroxaban or yagin or ym 150 or ym150 or LY517717 or darexaban or edoxaban or SSR126517E or fidexaban or idrabiotaparinux
or letaxaban or tanogitran or taxexaban).tw,nm.
20. heparin/ or exp heparin, low-molecular-weight/ or heparinoids/
21. (heparin$ or lmwh$ or enoxaparin$ or glycosaminoglycan$ or nadroparin$ ormesoglycan$ or tedelparin$ or certoparin or tinzaparin
or parnaparin or dalteparin or reviparin or fraxiparin$ or danaparoid or lomoparan or org 10172 or mesoglycan or pentosan polysul$
or sp54 or sp-54 or cy222 or cy-222 or cy216 or cy-216 or dermatan sul$ or heparan sul$).tw,nm.
22. or/5-21
23. Randomized Controlled Trials as Topic/
24. random allocation/
25. Controlled Clinical Trials as Topic/
26. control groups/
27. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or






33. randomized controlled trial.pt.
34. controlled clinical trial.pt.
35. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
36. (random$ or RCT or RCTs).tw.
37. (controlled adj5 (trial$ or stud$)).tw.
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38. (clinical$ adj5 trial$).tw.
39. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
40. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
41. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
42. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
43. (placebo$ or sham).tw.
44. trial.ti.
45. (assign$ or allocat$).tw.
46. controls.tw.
47. or/23-46
48. 4 and 22 and 47
49. exp animals/ not humans.sh.
50. 48 not 49
51. atrial fibrillation.ti.
52. 50 not 51
Appendix 3. EMBASE (Ovid)
1. brain infarction/ or brain stem infarction/ or cerebellum infarction/ or exp brain ischemia/ or carotid artery disease/ or exp carotid
artery obstruction/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp occlusive cerebrovascular disease/ or stroke patient/
2. (isch?emi$ adj5 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$
or occlus$ or hypoxi$)).tw.
4. 1 or 2 or 3
5. exp anticoagulant agent/
6. anticoagul$.tw.
7. antithromb$.tw.
8. coumarin derivative/ or 4 hydroxycoumarin/ or 4 hydroxycoumarin derivative/ or acenocoumarol/ or coumarin/ or dicoumarol/ or
ethyl biscoumacetate/ or phenprocoumon/ or warfarin/ or phenindione/
9. antivitamin k/
10. (warfarin$ or coumadin$ or coumarin$ or cumarin$ or phenprocoum$ or phenprocum$ or dicoumar$ or dicumar$ or aceno-
coumar$ or acenocumar$ or fluindione or phenindione or clorindione or diphenadione or ethyl biscoumacetate).tw.
11. (Vitamin K antagonist$ or VKA or VKAs or antivitamin K).tw.
12. exp thrombin inhibitor/
13. ((direct$ adj5 thrombin adj5 inhib$) or DTI$1).tw.
14. (argatroban or MD805 or MD-805 or dabigatran or ximelagatran or melagatran or efegatran or flovagatran or inogatran or
napsagatran or bivalirudin or lepirudin or hirudin$ or desirudin or desulfatohirudin or hirugen or hirulog or AZD0837 or bothrojaracin
or odiparcil).tw.
15. blood clotting factor 10a inhibitor/
16. ((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5 inhib$).tw.
17. (activated adj5 (factor X or factor 10) adj5 inhib$).tw.
18. xabans.tw.
19. (antistasin or apixaban or betrixaban or du 176b or eribaxaban or fondaparinux or idraparinux or otamixaban or razaxaban or
rivaroxaban or yagin or ym 150 or ym150 or LY517717 or darexaban or edoxaban or SSR126517E or fidexaban or idrabiotaparinux
or letaxaban or tanogitran or taxexaban).tw.
20. heparin derivative/ or heparin/ or heparinoid/ or exp low molecular weight heparin/
21. (heparin$ or lmwh$ or enoxaparin$ or glycosaminoglycan$ or nadroparin$ ormesoglycan$ or tedelparin$ or certoparin or tinzaparin
or parnaparin or dalteparin or reviparin or fraxiparin$ or danaparoid or lomoparan or org 10172 or mesoglycan or pentosan polysul$
or sp54 or sp-54 or cy222 or cy-222 or cy216 or cy-216 or dermatan sul$ or heparan sul$).tw.
22. or/5-21
23. Randomized Controlled Trial/
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27. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical
trial/
28. Double Blind Procedure/
29. Single Blind Procedure/ or triple blind procedure/
30. placebo/
31. (random$ or RCT or RCTs).tw.
32. (controlled adj5 (trial$ or stud$)).tw.
33. (clinical$ adj5 trial$).tw.
34. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
35. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
36. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
37. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
38. placebo$.tw.
39. trial.ti.
40. (assign$ or allocat$).tw.
41. controls.tw.
42. or/23-41
43. 4 and 22 and 42
44. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not
(human/ or normal human/ or human cell/)
45. 43 not 44
46. (atrial fibrillation or myocardial or coronary or cardiac or heart or renal or subarachnoid or arteritis or hypertens$ or aortic or cancer
or pregnan$ or dementia or diabetes or sickle cell or aneurysm$ or cardiopulmonary or migrain$).ti.
47. 45 not 46
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F E E D B A C K
Conclusions too weak, 25 June 2007
Summary
This review of anticoagulant trials, including over 22,000 patients with acute ischemic stroke, found no net benefit with the use of any
anticoagulant. Consequently, the implications for practice and implications for research are too timid. The implication for practice
should say that anticoagulants should be contraindicated in patients with acute ischemic stroke. The implications for research should
say that further trials of anticoagulants in acute ischemic stroke would be unethical.
Reply
This comment was submitted before the 2008 update was performed. The wording of the Authors’ conclusions section has been
modified to be more in keeping with this comment.
Note: the response to this feedback was delayed by a number of unavoidable administrative factors.
Contributors
Commenter: David A Cundiff MD
Reply: Peter Sandercock
WH A T ’ S N E W
Last assessed as up-to-date: 10 November 2014.
Date Event Description
18 September 2014 New search has been performed We have searched the literature for new relevant stud-
ies to June 2014. We identified one small new ongo-
ing study, but did not identify any new studies for
inclusion. We have reformatted and updated the text
throughout
18 September 2014 New citation required but conclusions have not
changed
The conclusions are unchanged
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H I S T O R Y
Protocol first published: Issue 1, 1995
Review first published: Issue 1, 1995
Date Event Description
9 January 2009 Feedback has been incorporated Feedback on the previous version of this review had
not been incorporated. This omission has now been
rectified in this small revision to the 2008 update
7 November 2008 Amended Duplicate text in ’Updated’ event of 11 January 2008
has been deleted
17 March 2008 Amended Converted to new review format.
11 January 2008 New citation required but conclusions have not
changed
New co-author: Ayeesha Kamal has replaced Gordon
Gubitz.
11 January 2008 New search has been performed The searches have been updated to October 2007. Two
trials (ARGIS-12004;Chaudhary 2002), with 201par-
ticipants, were included in this update, bringing the
total number of trials to 24 involving 23,547 partic-
ipants. The text has been extensively revised and up-
dated
C O N T R I B U T I O N S O F A U T H O R S
Peter Sandercock designed the original 1993 review of anticoagulant versus control, double-checked the data and supervised the analysis
and writing of this report. Edward Kane did the new literature searches and helped reformat and rewrite this update.
Ayeesha Kamal did the new literature searches, extracted the new data , performed the analysis and helped rewrite the text of the 2008
update.
Carl Counsell prepared the first version of the review and helped with the analysis and text of subsequent updates.
D E C L A R A T I O N S O F I N T E R E S T
Dr Sandercock was the principal investigator of the International Stroke Trial and Dr Counsell was also on the Steering Committee of
this trial (IST 1997). Edward Kane has no conflicts of interest to declare.
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S O U R C E S O F S U P P O R T
Internal sources
• University of Edinburgh, UK.
External sources
• Wellcome Trust, UK.
• Medical Research Council, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticoagulants [adverse effects; ∗therapeutic use]; Brain Ischemia [∗drug therapy; prevention& control]; Randomized Controlled Trials
as Topic; Risk; Stroke [∗drug therapy; prevention & control]
MeSH check words
Humans
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